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A  comprehensive summary  of  the work  to be  incorporate in the thesis entitled
“STUDIES ON  MEDICINALLY INTERESTED COMPOUNDS” has been
described as under.
Chapter-1 :- STUDIES ON DIHYDROPYRIMIDINES.
Chapter-2 :- STUDIES ON PYRAZOLES.
Chapter-3 :- STUDIES ON DIHYDROPYRIDINES.
Chapter-4 :- STUDIES ON CYANOPYRIDINES.
Chapter-5 :- STUDIES ON QUINOLINES.
Chapter-1 :- STUDIES ON DIHYDROPYRIMIDINES.
Recently, the interest in the synthesis of the dihydropyrimidine derivatives is
increasing tremendously because of their therapeutic activities such as antiviral, antitumor,
antibacterial and antiinflammatory. Many of them are pharmacologically important since
they behave calcium chennal blockers,antihypertensive agents and  α1a antagonists.
In order to developing better medicinally important compounds, it  was consid-
ered of interest to synthesise some new dihydropyrimidinone and dihydropyrimidinethione
derivatives shown as under
SECTION - I :  SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-
ARYL-5-CARBOXYMETHYL-6-CYCLOPROPYL-3 ,4 -
DIHYDROPYRIMIDINE-2(1H)-ONES.
     2
NH
N
H
O
R
O
O
CH3
Type (I)                R =Aryl
The oxopyrimidines of  type (I) have been synthesized by  the condensation of
Methyl-3- cyclopropyl-3-oxo-propanoate with urea and arylbenzaldehydes in the pres-
ence of HCl.
SECTION - II :SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-
ARYLAMIDO-6-CYCLOPROPYL-4-(p-METHOXYPHENYL)-
3,4-DIHYDROPYRIMIDINE-2(1H)-ONES.
NH
N
H
O
NH
R
O
O
CH3
  Type (II)                                   R=Aryl
The oxopyrimidines of  type (II)  have been synthesized by the condensation of
N-Aryl-3-cyclopropyl-3-oxo-propanamide with urea and arylbenzaldehydes in the
presence of HCl.
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SECTION - III : SYNTHESIS AND THERAPEUTIC EVALUATION OF  4-
   ARYL-5-CARBOXYMETHYL-6-CYCLOPROPYL-3,4-
   DIHYDROPYRIMIDINE-2(1H)-THIONES.
NH
N
H
S
R
O
O
CH3
 Type (III)                R=Aryl
The thiopyrimidines of type (III) have been synthesized by  the condensation of
Methyl-3-cyclopropyl-3-oxo-propanoate with thiourea and arylbenzaldehydes in the
presence of HCl.
SECTION- IV: SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-
ARYLAMIDO-6-CYCLOPROPYL-4-(p-METHOXY PHENYL)-
3 , 4 -DIHYDROPYRIMIDINE-2(1H)-THIONES.
NH
N
H
S
NH
R
O
O
CH3
Type (IV)               R=Aryl
          The thiopyrimidines of type (IV)  have been synthesized by  the condensation of
N-Aryl-3-cyclopropyl-3-oxo-propanamide with thiourea and arylbenzaldehydes in the
presence of HCl.
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Chapter-2 :- STUDIES ON PYRAZOLES
        Pyrazole nucleus are endowed with a variety of biological activities such as
antiinflammatory, antitumor, fungicidal, antitubercular, amoebicidal, herbicidal,
anticonvulsant, hypnotic, CNS depressant, plant growth regulatory activity etc.
Our  efforts are focused on introduction of chemical diversity in the molecular frame
work in order to synthesizing active molecule of widely different composition.
Considering the increasing importance of pyrazole nucleus, we have synthesised
some novel pyrazolones, arylidines, pyrazolines  nucleus which have been described as
under
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-
N-SUBSTITUTED -5-CYCLOPROPYL-2 ,3 -DIHYDRO-
PYRAZOLE-3-ONES.
N NH
O
R
The pyrazolones  of type (V) have been synthesized by the condensation of Methyl-
3-cyclopropyl-3-oxo-propanoate and hydrzine hydrate in the presence of gla. acetic
acid.
  Type (V)                    R= H, Aryl
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SECTION-II : SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL
   -3-(o-CHLOROPHENYL)-2-(CYCLOPROPYLCARBONYL)-
   ACRYLAMIDES.
O
O
NH
Cl
R
  Type (VI)                             R=Aryl
The chalcones of type (VI)  have been synthesized by the condensation of
N-Aryl-3-cyclopropyl-3-oxo-propanamide with o-Chloro benzaldehyde.
SECTION-III :  S Y N T H E S I S  A N D  T H E R A P E U T I C  E VA L U AT I O N  O F
     4-ARYLAMIDO-5-(o-CHLOROPHENYL)-3-CYCLO PROPYL-
    4,5-DIHYDRO-1H-PYRAZOLES.
Cl
NH
N
NH
O
R
 Type (VII)                            R=Aryl
The pyrazoline derivatives of type (VII) have been synthesized by the  reaction
of  type (VI)  with hydrazine hydrate.
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           Type (VIII)             R=Aryl
N
N
NH
O
R CH3
O
Cl
SECTION-IV : SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-N-
    ACETYL-4-ARYLAMIDO-3-CYCLOPROPYL-5-(o-CHLORO-
    PHENYL)-4,5-DIHYDRO-1H-PYRAZOLES.
The pyrazoline derivatives of type (VIII) have been synthesized by the  reaction
of type (VI) with hydrazine hydrate in gla.acetic acid.
Chapter- 3:- STUDIES ON DIHYDROPYRIDINES
The synthesis and pharmacological evaluation of dihydropyridines are described,
these compounds have been found to possess  very promising αa1-adrenergic and
calcium chennal  blocking activities which are clinically used in the treatment of
hypertension and some other cardiac disorders, calcium chennal blocker are
increasingly becoming the drug of primary treatment  supported by β-blockers. It is
fore there worth while to synthesise and evaluate compounds having pharmacophores of
both the types of drugs.The existing drugs having dihydropyridines and associated with
pharmacological activity are namely NEFEDIPINE, NICARDIPINE, NIMODIPINE,
NILVODIPINE, FELODIPINE, ISRADIPINE, DAZODIPINE, AMLODIPINE,
RIODIPINE, FLORDIPINE, NITREDIPINE and many more. Among these
dihydropyridines only amlodipine (I) and structurelly related new  recently synthesised
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UK-74,505 are having chloro subtitution in ortho position in phenyl ring attached to
DHP nucleus.
These observations prompted us to synthesise some halogen represented sym-
metric and asymmetric dihydropyridine derivatives which may  possess better pharma-
cological activity.
 In order to achieving better therapeutic activity we have synthesised some novel
symmetric dihydropyridines and assymmetric dihydropyridines which have been
described as under
SECTION-I :SYNTHESIS AND THERAPEUTIC EVALUATION OF 3,5-
DI-ARYLAMIDO-2,6-DICYCLOPROPYL-4-(p-METHOXYPHENYL)-
1,4-DIHYDROPYRIDINES.
O
CH3
N
H
O
NH
R
O
NH
R
 Type (IX)            R=Aryl
The dihydropyridines of type (IX) have been synthesized by the condensation of 2
moles of N-Aryl-3- cyclopropyl-3-oxo-propanamide, p-methoxy benzaldehyde and
ammonia.
SECTION-II : SYNTHESIS AND THERAPEUTIC EVALUATION OF METHYL
  -5-ARYLAMIDO-4-(o-CHLOROPHENYL)-6-CYCLOPROPYL-2-
  METHYL-1,4-DIHYDROPYRIDINE-3-CARBOXYLATES.
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N
H
CH3
OO
NH
R
O
CH3
Cl
Type (X)                    R=Aryl
The dihydropyridines of type (X) have been synthesized by the condensation of
N-Aryl-3-cyclopropyl-3-oxo-propanamide  and methyl-3-amino crotonate with o-Chloro
benzaldehyde.
Chapter-4 :- STUDIES ON CYANOPYRIDINES
Pyridine nucleus plays an important role in medicine, agriculture and industrial
chemistry. Cyanopyridine possess antibacterial, antifungal, antidiabetic, anticholesterimic
and antihypertensive activity. They have been also used as dyes for cotton and polyester
fabrics. These findings prompted us to synthesize some new cyanopyridine derivatives
possessing better therapeutic values, which have been described as under
SECTION-I :SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYL
AMIDO-4-(o-CHLOROPHENYL)-3-CYANO-6-CYCLOPROPYL-2-
METHOXY  PYRIDINES.
N
O
NH
R
O
CH3
N
Cl
Type (XI)            R=Aryl
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Cyanomethoxypyridines of type (XI) have been synthesized by the  condensa-
tion of N-Aryl-3-cyclopropyl-3-oxo-propanamide,o-Chlorobenzaldehyde with
malononitrile and  sodium  methoxide.
SECTION-II : SYNTHESIS AND THERAPEUTIC EVALUATION OF 5- ARYL
            AMIDO-4-(o-CHLOROPHENYL)-3-CYANO-6-CYCLOPROPYL-
            2-ETHOXY PYRIDINES.
Type (XII) R= Aryl
Cyanoethoxypyridines of type (XII) have been synthesized by the  condensation
of N-Aryl-3-cyclopropyl-3-oxo-propanamide,o-Chlorobenzaldehyde with malononitrile
and  sodium  ethoxide.
CHAPTER-5 :-STUDIES ON QUINOLINES.
Quinoline and its derivatives have received considerable attention in medicinal
chemistry. The quinoline nucleus is a prominent structural feature in a variety of natural
products as well as in other compounds of medicinal interest. Quinoline derivatives are
reported to possess anticonvulsant, tuberculostatic, hypnotics, sedative, antihypertensive,
antibacterial, antifungal and many other therapeutic activities. Considering the increasing
importance of quinoline nucleus, the synthesis of some novel quinoline derivatives has
been undertaken.
N
O
NH
R
O
N
Cl
CH3
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2-Cyclopropyl quinolines of type (XIII) have been synthesized by the condensa-
tion of  N-Aryl-3-cyclopropyl-3-oxo-propanamide with 2-Amino-3,5-dibromo ben-
zaldehyde in the presence of methan sulphonic acid.
SECTION-II : SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-CYCLO-
  PROPYL-5,6,7,8-SUBSTITUTED-1,2-DIHYDRO QUINOLINE-
  2-ONES.
  Type (XIII) R=  aryl
N
Br
Br
O
NH
R
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL
 AMIDO-6,8-DIBROMO-2-CYCLOPROPYL QUINOLINES.
Type (XIV)
N
H
O
R1
R2
R3
R4
R1,R2,R3,R4=Cl,CH3
OCH3,NO2...
4-Cyclopropyl quinolines of type (XIV) have been synthesized by the cyclisation
of N-Aryl-3- cyclopropyl-3-oxo-propanamide with concentrated sulphuric acid.
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CHARACTERISATION
The constitution of newly synthesised products have been supported by using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
In vitro study on multiple biological activities.
All the compounds have been evaluated for their antibacterial activity towards
differents Gram positive and Gram negative bacterial strains and antifungal
activity towards Aspergillus niger at a concentration of 40μg. The biological
activity of the synthesised compounds have been compared with standard drugs.
   Signature of guide         Signature of student
    (Dr. Viral R. Shah)          (Mr. Mahesh C. Patel)
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INTRODUCTION
“STUDIES ON MEDICINALLY  INTERESTED COMPOUNDS”
The primary objective of medicinal chemistry is the design and discovery of
new compounds that are suitable for use as drugs. This process requires a team effort. It
not only involves chemists but also workers from a wide range of disciplines such as
biology, biochemistry, pharmacology, computing and medicine amongst others.
Chemistry related with pharmaceutically important compounds is mainly divided
in two parts. The first chemotherapy, concerns the treatment of infections, parasites or
malignant diseases by chemical agents, usually substances that shows selective toxicity
towards the pathogen. The other division relates to diseases of bodily disfunction and
the agents employed are mainly compounds that effect the functioning of enzymes, the
transmission of nerve impulses or the action of hormones on receptors.
Research in the field of pharmaceutical has its most important task in the devel-
opment of new better drugs and their successful introduction into clinical practice.
Central to these efforts, accordingly stand the search for pharmaceutical substances and
preparation which are new and original. In addition to these objectives, we may search
for newer drugs which exhibit some clear advantages over a drug already known. Such
advantages may be qualitative or quantitative improvement in activity, the absence of
undesirable side effects, lower toxicity, improved stability or decreased cost.
Heterocyclic compounds show vital role in the field of pharmaceuticals.  Hetero-
cyclic compounds are used because they have a specific clinical reactivity, for example
epoxides, aziridines and  β-lactams. The introduction of heterocyclic group into drugs
may affect their physical properties, for example the dissociation constants of sulpha
drugs or modify their patterns of absorption, metabolism or toxicity.
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The word ‘drug’ is derived from the french word ‘drogue’ which means a dry
herb. According to “WHO” a drug may be defined as “any substance or product which
is used or intended to be used for modifying or exploring physiological  system or patho-
logical status for the benefit of recipient”.
Drugs action is believed to be due to the interaction of the drug with enzymes,
receptors and other molecules found in the biological system. The binding of a drug to the
active or other sites of an enzyme usually has the effect of preventing the normal operation
of that enzyme. The drug’s therapeutic effect will depend on the stability of the drug-
enzyme complex as well as the fraction of active and allosteric sites occupied by the
drug. The stronger the binding of the drug to the enzyme and greater the number of sites
occupied, the more effective the drug is likely to be in inhibiting the action of the
enzyme.
The degree of drug activity is directly related to the concentration of the drug in
the aqueous medium in contact with the active or receptor site. The factors affecting this
concentration in a biological system can be classified in to two phase.
(I) The pharmacokinetic phase
It is concerned with the study of the parameters that control the journey of the
drug from its point of administration to its point of action. It includes the absorption,
distribution, metabolism and elimination of a drug.
(II) The pharmacodynamic phase
It is concerned with the result of the interaction of drug and body at the receptor
site, that is, what the drug does to the body. This includes physiological and biochemi-
cal effects of drugs and their mechanism of action at macromolecular /subcellular organ
systems.
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The role of the medicinal chemist is to design a drug structure that has the
maximum beneficial effects with a minimum of side effects. This design has to take into
account the stereoelectronic characteristics of the target active or receptor site and also
such factors as the drug’s stability in situ, its polarity and its relative solubilities in
aqueous media and lipids. The stereochemistry of the drug is particularly important
because stereoisomers often have different biological effects that range from inactive
to highly toxic.
In the nineteenth century, chemistry was developed as a science, both in terms of
experimental procedures and scientific theory. Scientist isolated and purified single
compounds from natural extracts. Method of organic synthesis were developed that helped
chemists altering structures in a predictable way. The chemists started separating out the
various components of ancient positions to discover whether a single compound was
responsible for the medicinal effect known as the active principle.
A large number of important drugs have been introduced during the period of
1940 to 1960. This period is known as ‘Golden Period’ of new drug discovery. Thus
starting from 1933-the first antibacterial drug prontosil leading to various sulpha drugs;
1940-penicillin, antibiotics; 1945-chloroquine, antimalarial; 1950-methyldopa, antihy-
pertensive; 1957-chlorthiazide, diuretic; 1958-adrenergic beta blockers coronary
vasodilatory; 1960-semi synthetic penicillin, antibacterial; 1965-trimethoprim,  antimi-
crobial; 1967-disodium chromoglycoate, antiallergic; 1972-cimetidine, H2-antagonist;
1975-verapamil, calcium antagonist; 1981-captopril, antihypertensive. There are some
specific examples representing new therapeutics.
AIMS AND OBJECTIVES
In the pharmaceutical field, there have always been and will continue to be a
need for new and novel chemical inhibitors of biological function.Our efforts are
focused on the introduction of chemical diversity in the molecular frame work in order to
synthesizing pharmacologically interesting compounds of widely different composition.
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During the course of our research work, looking to the application of hetero-
cyclic compounds, several entities have been designed, generated and characterized
using spectral studies. The details are as under.
♦ To generate several derivatives like dihydropyrimidine, dihyrdopyridine, pyrazoline,
cyanopyridine, quinoline  bearing β -keto ester nucleus.
♦ To check purity of all the compounds using thin layer chromatography.
♦ To characterise these products for stucture elucidation using spectroscopic
techniques like IR, 1HNMR and Mass spectral studies.
♦ To evaluate new products for better drug potential against different strains
of bacteria and fungi for biological activity.
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INTRODUCTION:
Many aryl substituted 3,4-dihydropyrimidin-2-ones (DHPMs) and their
derivatives are an important class of compounds in the field of drugs and pharmaceuticals1.
They are found to exhibit a wide range of biological activities2 such as antibacterial,
antiviral, antitumour, antiinflammatory. Most of the DHPMs and their derivatives are
medicinally important as calcium channel blockers, antihypertensive agents,α1a-
antagonists and anti HIV agents3. The biological activities of some marine alkaloids
isolated recently have been attributed to the presence of a dihydropyrimidinone moiety4.
In 1893, the synthesis of functionalized 3,4-dihydropyrimidin-2(1H)-ones (DHPMs) via
three-component condensation reaction of an aromatic aldehyde, urea and ethyl
acetoacetate was reported for the first time by P. Biginelli5 . In the past decades.
Such Biginelli-type dihydropyrimidones have received a considerable amount of
attention due to the interesting pharmacological properties associated with this
heterocyclic scaffold. Pyrimidine ring system occurs widely in living organisms. Purines,
uric acid, barbituric acid and anti-malarial and antibacterial agents also bear the pyrimidine
skeleton. The chemistry of pyrimidine has been widely studied.
Recently, interest has shifted from DHPM calcium channel modulators to other
biologically active DHPM derivatives, e.g. α1a- adrenoceptor selective antagonists which
are useful for the treatment of benign prostatic hyperplasia 6. Again, the pharmacological
activity in the area of α1a-adrenergic antagonists is based on activity found earlier in
the DHP series of compounds. However, dihydropyrimidones of type (I) represent much
more than just being aza analogues of dihydropyridines of the Hantzsch type (II).
N
N
Ar
E H
X
H
R6 N
E
R6
H
R2
E
Ar
DHPM DHP
E = ester, amide, acyl
R2,R6 = alkyl
X = O, S
Ar = substituted aryl 
(I) (II)
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SYNTHETIC ASPECTS :
1. In 1893 Pietro Biginelli reported the first synthesis of dihydropyrimidines
(III) by a simple one-pot condensation reaction of ethyl acetoacetate, benzalde
hyde and urea under strongly acidic condition5,7.
2. DHPM-2(1H)-ones were prepared in high yield by Biginelli condensation
of an aldehyde, dicarbonyl compound and urea in ethanol using Mn(OAc)3
as a catalyst8.
3. Substituted 3,4-DHPM-2(1H)-ones were prepared in high yield by Biginelli
condensation of an aldehyde, dicarbonyl compound and urea in ethanol
using CoCl2.6H2O catalyst
9.
4. Subhas D. Bose et al.10 describe a general and practical route for the Biginelli
cyclocondensation reaction using cerium(III) chloride (CeCl3)heptahydrate as
catalyst.
5. A simple effective synthesis of DHPM-2-(1H)-one derivatives, using boric acid
as a catalyst from an aldehyde 1,3-dicarbonyl compound and urea in glacial
acetic acid is described by Tu Shujang et al.11 Compared with the classical
Biginelli reaction conditions, this new method has the advantage of excellent yield
86-97% and the short reaction time (0.5-2hr).
6. Silica sulfuric acid efficiently catalyses the three component Biginelli reaction
between an aldehyde, α,β-cabonyl compound, and thiourea in ethanol  to afford
the corresponding dihydropyrimidines (IV) in high yield by Salehi Peyman et al.12
The catalyst is reusable and can be applied several times without any decrease in
the yield of the reaction.
CH3 O
EtOOC
+ Ph CHO +
NH2 NH2
O H+ NH
N
H
Ph
OCH3
EtOOC
(III)
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                                                                                                     (IV)
7. DHPM was prepared from three component β-diketone, aldehyde and thiourea
coupling in ethanol catalyse by indium(III) tribromide(InBr3).
13,14 This modified one-pot
Biginelli condensation provided not only simple preparation but also this modified
Biginelli reaction was oxygen-bridge.
8. Ethyl-2-(methylthio)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylate (V) has been
investigated by M.A.Hassan et al.15 by the reaction of 5-carboethoxy-2-thiouracil,
methyl iodide with the use of tetra butylammonium bromide (PTC) as a catalyst with
continuous efficient stirring for 4-6 hrs at 700C.
                                                                                       (V)
CH3 O
EtOOC
+ Ph CHO +
NH2 NH2
S NH
N
H
Ph
SCH3
EtOOC
Silica H2SO4
N
NH
SH
O O
O CH3
N
NH
H3CS
O O
O CH3
TBAB, CH3I
Stirring  4-6 h
REACTION MECHANISM
Since the 1930s several mechanistic pathways have been proposed for the Biginelli
reaction. In 1933, Folkers and Johnson reported that one of three intermediats(VI),
(VIII) was likely present in this reaction16. These included bisureide (VI) which was
formed by a condensation reaction between the arylaldehyde and the urea followed by
subsequent attack of the resultant imine with another equivalent of urea. Also, (VI)
urido ethyl acrylate (VII) arose from a condensation reaction between of the β-ketoester
and urea Finally, the reaction of the β-ketoester and the aldehyde delivered the aldol
adduct (VIII).
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NH NH2
O
Ph NH
NH2 O
EtOOC
CH3 N
NH2
H
O
CH3 OEt
O O
Ph
(VI) (VII) (VIII)
Fourty years after the initial proposal, Sweet and Fissekis proposed a more
detailed pathway involving a carbenium ion species17.  According to these authors the
first step involved an aldol condensation between ethyl acetoacetate (IX) and
benzaldehyde (X) to deliver the aldol adduct (XI). Subsequent dehydration of (XI)
furnished the key carbenium ion (XII) which was in equilibrium with enone (XIII).
Nucleophilic attack of (XII) by urea then delivered ureide (XIV). Intramolecular
cyclisation produced a hemiaminal which underwent dehydration to afford
dihyropyrimidinone (XV). These authors demostrated that the carbenium species was
viable through synthesis. After enone (XIII) was synthesised, it was allowed to react
with N-methyl urea to deliver the mono-N-methylated derivative of DHPM (XV).
CH3 OEt
O O
+ Ph H
O
OH
CH3 O
Ph
EtOOC
+H -H2O
CH3 O
Ph
EtOOC +
EtOOC
Ph
CH3 O
NH2 NH2
O
NH
CH3 O
Ph
EtOOC
NH2
O
NH
N
H
O
Ph
CH3
EtOOC
-H2O
+H
(IX) (X) (XI)
(XIV) (XII)
(XV)
(XIII)
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The mechanism was then reexamined 25 years later in 1997 by Kappe18.  Kappe
used 1H and 13CNMR spectroscopy to support the argument that the key intermediate
in the Biginelli reaction was iminium species (XVII).In the event, benzaldehyde reacted
with urea to form an intermediat "hamiaminal" (XVI) which subsequently dehydrated to
deliver (XVII).Iminium cation (XVII) then reacted with (IX) to give (XIV), which
underwent facile cyclodehydration to give (XV).Kappe also noted that in the absence of
(IX), bisureide (VI) was afforded as a consequence of neucliophilic attack of (XVII) by
urea.This discovery confirmed the conclusion of Folkers and Johnson in 1933. As far as
the proposal form 25 years earlier by Sweet and Fissekis, kappe saw no evidence by
1H and 13C NMR spectroscopy that a carbenium ion was a required species in the
Biginelli reaction. When benzaldehyde (X) and ethyl acetoacetate(IX) were mixed under
Biginelli conditions the requisite aldol product (XI), which was necessary for the formation
of carbenium ion (XII) was not detected.
Ph H
O
NH2 NH2
O
Ph N
OH
NH2
O
H
+H
Ph N NH2
O
H
+
-H2O
NH2 N N NH2
Ph O
HH
O
CH3
OEt
O
O
NH
NH2 O
Ph
CH3
EtOOC
O
NH
N
H
O
Ph
CH3
EtOOC
(XVI) (XVII)
                          (XV)                                       (XIV)                            (VI)
                                                                                             (IX)
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THERAPEUTIC IMPORTANCE
Pyrimidines are among those molecules that make life possible, have been some
of the building blocks of DNA and RNA. Several analogs of  pyrimidines have been
used as compounds that interfere with the synthesis and functioning of nucleic acids e.g.
fluorouracil, which has been used in cancer treatment.
From the biochemical point of view, dihydroazines are of intense interest because
the presence of this group at the active site of the “hydrogen transferring coenzyme”
NADH (reduced nicotinamide adenine dinucleotide). This nucleotide, a central participant
in metabolic processes in living organisms, participates in the reduction of various
unsaturated functionalities.
In the area of drug development, dihydroazines show great promise, particularly
since the 4-aryldihydropyridines exhibit powerful vasodilation activity via modifying the
calcium ion membrane channel19-23. Additionally, dihydropyridines have been found to
actively transport medication across biological membranes24.
Until recently, most of the information available on dihydroazines centered around
dihydropyridines, with very little data extending to the related dihydropyrimidines.
Dihydropyrimidines of Biginelli-type have come a long way since their discovery
in 1893 and the first patent on DHPM derivatives in 1930, describing agents for the
protection of wool against moths25.
Dihydropyrimidinethiones have attracted considerable attantion as they appeared
of interest to possess wide range of therapeutic activities. Different activities are as
under
1. Antiviral26-29
2. Antibacterial30
3. Antitumor31-33
4. Cardiovascular34-36
5. Antiplasmal37
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6. Anticarcinogenic38
7. Calcium channel modulator39-42
8. Antihypertensive43-45
9. Vasodilator46
10. Blood platelet-aggregation inhibitor47-49
11. Antiinflammatory50-51
12. Analgesic50
13. Antilukemic52
14. α1a-Adrenergic receptor antagonist53,54
15. Coronary dilatory55
16. Anti-ichemic56
17. Neuropeptide Y (NPY) antagonist57
18. Mitotic Kinesin inhibitor58
19. Metabotropic glutamate receptor antagonist59
Calcium ion plays a vital role in a large number of cellular processes, including
excitation-contraction and  stimulus-secretion.60-62 In recent years interest has also
focused on aza-analogs such as dihydropyrimidines (I) which show a very similar
 pharmacological profile to classical dihydropyridine calcium channel modulators.63-69
N
N
H
O
O
O2N
CH3
O
i-Pr CONH2
(I)
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N
N
R2
R3
CH3
R1COO
R4
N
NCl
CH3
EtOOC
CH3 CH3
NaOOC
 (II) (III)
Hidetsura Cho et al.63 have synthesized the novel calcium channel antagonists
3-N-substituted-3,4-dihydropyrimidines and 3-N-substituted-dihydropyrimidin-2(1H)
-ones were regioselectively synthesized in good yields. Efforts of Atwal  K. S. et al.70 in
this area have resulted  in the discovery of dihydropyrimidines (II) and (III) as potent
AII receptor antagonists.
Dhanapalan N. et al.71  prepared dihydropyrimidinones (IV) exhibited high binding
affinity and subtype selectivity for the cloned human a1a receptor. James C. et al.
72
explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via
C-5 amide as selective a1a receptor subtype antagonists. Several recently isolated marine
alkaloids with  interesting biological activities also contain dihydropyrimidinone nucleus.
Patil A.D.et al.73-74 described that a novel class of polyguanidine alkaloids isolated from
the red Caribbean sponge Batzella sp
N
N
H
CH3
O
O
CH3
N
O
NO2
O
N
Ph
COOMe
H
(IV)
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Atwal K. S. et al.75 have described  the potent antihypertensive activity of the
modestly active  dihydropyrimidine calcium channel blocker. Kappe C. O. et al.76
synthesised the polycyclic DHPM derivatives.Muralidhar T. G. et al.77 have synthesised
several DHPM-one analogues, among this (V) and (VI) gave excellent  selectivity
(>880-fold) over a1b and a1d and also showed good selectivity over several other
recombinent human G-protein coupled receptors.
N
N
H
O
H2N N
O
F
O
N
Ph
CN
CH3
F
H
N
N
H
MeOOC
N
O
F
O
N
Ph
CH3
O
CH3
F
H
 (V)             (VI)
NH
N
O
O
CH3
OH
N3
NH
N
O
O
CH3
OH
N3
 (VII)  (VIII)
Victor E.et al.78synthesised 5’-triphosphates of (VII) and (VIII) evaluated directly
as reverse transcriptase (RT) inhibitors using both a recombinent enzyme and enzyme
obtained and purified directly from wild-type viruses.
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Sanjay Batra et al.79 have synthesised 5-arylmethyl-4-imino-3-aryl-3,4-dihydro-
1H pyrimidin-2-ones which were tested for their antibacterial activity. Mai A. and
co-workers80 have investigated the dihydropyrimidines which are highly active against
HIV-1. Herve Geneste and co-workers81 synthesized substituted 1H-pyrimidin-2-one
with selective dopamine D3-receptor antagonists activity. Biginelli compound shows a
diverse range of biological activities. As early as 1930 simple derivatives of (IX) were
patented as agent for the protection of  wool against moths by Dondoni A. et al.82Later,
interest focused on the antiviral activity of Biginelli compounds.83
NH
N SCH3
O
CH3
Cl
O
NH
N
H
SCH3
Ph H
NH2
O
(IX)    (X)
Pyrimidine-5-carboxamides derivatives of (X) were reported to possess
anticarcinogenic activity,84antiinflammaroty,85 analgesic86 and blood platelet       aggre-
gation inhibitory activity. 87
A very recent highlight in this context has Abeen the identification of the structur-
ally rather simple DHPM monastrol (XI) as a novel cell-permeable molecule that blocks
normal bipolar spindle assembly in mammalian cells and therefore causes cell cycle
arrest.88  Haggarty S. J. et al.89 suggested that monastrol specifically inhibites the
mitotic kinesin Eg 5 motor protein and can be considered as a new lead for the
development of anticancer drugs. George C.et al.90 prepared dihydropyrimidine (XII)
was equipotent to nifedipine and amlodipine in vitro. In the spontaneously hypertensive
rat, dihydropyrimidine (XII) is both more potent and longer acting than nifedipine and
compares most favourably with the long-acting dihydropyridine derivative of amlodipine.
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Dihydropyrimidine (XII) has the potential advantage of being a single enantiomer.
Sally-Ann P.et al.91 synthesised 4,6-Bis[(R-carbamoylethyl)thio]-1-
phenylpyrazolo[3,4-d]pyrimidine and identified as a novel adenosine A1  receptor
antagonist, antagonizing adenosine-stimulated cyclic adenosine monophosphate
generation in guinea pig brain slices.92,93
New drug molecules under clinical study:
Recently many new molecules which are under study from phase-I to Phase-IV
clinical trials for different pharmacological action have shown that the basic characteristic
of morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under
NH
N
H
SCH3
OH
EtOOC
       (XI)
N
N
H
SCH3
COO
CF3
PriOOC N
F(XII)
N
H
N
CH3 CH3
O
O
CH3
N
H
NH
O CH3
O
CH3
NO2
Treatment of Hypertension
Calcium Channel Blokers
Calcium Channel Blokers94
Company Name: Merck & Co.
     27
Moreover one compound95 is very active against Non-nucleoside inhibitor of
human hepatitis B virus (IC50 = 53 nM for reduction of HBV DNA in human hepatoma
HepG2.2.15 cells) with low cytotoxicity in uninfected cells (CC50 = 7 mcM). Compound
inhibited both viral DNA and viral cores in HepG2.2.15 cells and HBV-transfected cell
lines, whereas it did not affect the activity of endopolymerase and had no effect on other
DNA or RNA viruses. In vivo in a transgenic mouse model, oral doses of 3-100 mg/kg
b.i.d. or t.i.d. for up to 28 days dose-dependently.
Decreased viral DNA in the liver and plasma with efficacy comparable to
lamivudine. However, unlike lamivudine, compound reduced cytoplasmic HBV core
antigen (HBcAg) in the liver of mice. Pharmacokinetic studies in mice showed rapid
absorption, 30% bioavailability and dose-proportional plasma levels.
N
H
NH
CH3
O
O
N
FF
CH3
Cl
F
    Name : Bay-41-4109
   Anti Hepatitis B Virus Drugs96
    Bayer
               calcium channel blocker97
N
N
O
OO
O
CH3 CH3
NO2
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N
CH3
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CH3
MAR-99
Leukotrine Antagonist98
(Known anti-asthmatic agent, now reported to pos-
sess anti-ulcerative and gastric antisecretory activi-
ties, which inhibits hydrochloric acid-ethanol-,
stress- and indomethacin-induced ulcers in rat.
Calcium Channel Blockers99
N
NH
NH2
F
O
Flucytosine
(fluorocytosine)
Antifungal Agent.100
In vitro susceptibility of Candida
species isolated from cancer patients
against some antifungal agents.
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Antimalarial
Agent.101
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N
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OH
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Dipyridamole Acute Myocardial Infection
Treatment of Antiplatlet
Therapy.
N
NHNH
NH
N
Cl
Cl
Cl
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O CH3
O
Immunosuppressants
Oncolytic Drug
     30
N
H
N
O
OH
NH
CH3 CH3
O
Antibacterial Drugs
39th Intersci  Conf Antimicrob Agents
Chemother (Sept 26-29, San Francisco)
1999, Abst F1808
In vitro activity of novel 6-anilinouracils
targeted to DNA polymerase III of Gram-
positive bacteria
N
NH
S
CH3
CH3O
O
O
CH3
TNK-6123
TNK-6123
Anti HIV Agent
Reverse Transcripase Inhibitors.
Non-nucleoside HIV-1 reverse transcriptase
inhibitor
Compound was active not only against wild-
type HIV-1 strains (IC50 = 3 nM against IIIB
and NL4-3 HIV-1 strains) but also showed
nanomolar
With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidines which have been
described in following sections
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SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
4-ARYL-5-CARBOXYMETHYL-6-CYCLOPROPYL-
3,4-DIHYDROPYRIMIDINE-2(1H)-ONES.
SECTION - II : SYNTHESIS AND THERAPEUTIC EVALUATION OF
5-ARYLAMIDO-6-CYCLOPROPYL-4-(p-METHOXY-
PHENYL)-3,4-DIHYDROPYRIMIDINE-2(1H)-ONES.
SECTION - III : SYNTHESIS AND THERAPEUTIC EVALUATION OF
4-ARYL-5-CARBOXY METHYL-6-CYCLOPROPYL-3,4-
DIHYDROPYRIMIDINE-2(1H) -THIONES.
SECTION- IV:     SYNTHESIS AND THERAPEUTIC EVALUATION OF
    5-ARYLAMIDO-6-CYCLOPROPYL-4-(p -METHOXY-
    P H E N Y L ) - 3 , 4 - D I H Y D R O P Y R I M I D I N E - 2 ( 1 H ) -
    THIONES.
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYL-5-CARBOXY
METHYL-6-CYCLOPROPYL-3,4-DIHYDROPYRIMIDINE-2(1H)-ONES.
The broad spectrums of pharmacological properties have been demonstrated
by the dihydropyrimidinone nucleus.Inspired by these facts, novel dihydropyrimidinone
derivatives of type (I) have been synthesized by the condensation of Methyl-3-
cyclopropyl-3-oxo-propanoate, urea and aryl aldehydes in the presence of catalytic
amount of con. HCl.
NH
N
H
O
R
O
O
CH3
         Type (I)      R =Aryl
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
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+
R= Aryl
NH
N
H
O
O
O
R
CH3
R
O
+
NH2 NH2
O
Hydrochloric acidEthanol
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IR SPECTRAL STUDIES OF 5-CARBOXY METHYL-6-CYCLOPROPYL-4-PHENYL-3,4-
DIHYDROPYRIMIDINE-2(1H)-ONES.
Alkane C – H str.(asym.) 2958 2975-2950 102
–CH3 C – H str. (sym.) 2845 2880-2860 "
C – H def. (asym.)                          1466 1470-1435 "
 –C–CH2 C – H def.                                       1398 1385-1365 "
 Aromatic C – H str.                                        3103 3090-3030 "
C = C str                                         1513 1612-1550 "
                                                       1493 1580-1450 "
C – H i.p. (def)                               1177 1177-1027 "
C – H o.o.p. (def)                             819 832-802 "
Pyrimidine C = C str. 1592 1580-1520 103
N – H str. 3341 3440-3300 "
C = O str. 1669 1660-1700 "
Ester C =O                                               1705 1730-1700 "
C – O – C 1240 1260-1200 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
NH
N
H
O
O
O
CH3
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Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons Inference
1. 0.86-1.19                m               4H                       HC–(CH
2
)
2
2. 2.99-3.13                m               1H                       (H
2
C)
2
–CH
3. 3.49-3.55               s               3H                           -OCH
3
4. 5.15-5.17                              s                                  1H                          Pyrm-CH
      5.               7.21-7.37                m               5H                            Ar-H
6. 7.81                s               1H                            N–H
      7.                  8.23                s               1H                            N–H
Internal Standard : TMS; Solvent : DMSO : Instrument : BRUKER Spectrometer (200 MHz)
NMR SPECTRAL STUDIES OF  5-CARBOXY METHYL-6-CYCLOPROPYL-4-PHENYL-3,4-
DIHYDROPYRIMIDINE-2(1H)-ONES.
NH
N
H
O
O
O
CH3
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ANTIMICROBIAL ACTIVITY
Method : Cup-Plate104
Gram positive bacteria : S. aureus
Bacillus coccus
Gram negative bacteria : P.aeruginosa
Aerogenes
Fungi : A.niger
Concentration           : 40μg
Solvent : Dimethylformamide
Standard drugs : Amoxicillin, BenzoylPenicillin,
Ciprofloxacin, Erythromycin,
Griseofulvin
The antimicrobial activity was compared with standard drugs like  Amoxicillin,
BenzoylPenicillin,  Ciprofloxacin, Erythromycin and antifungal activity was compared
with  Griseofulvin. The zones of inhibition were measured in mm.
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EXPERIMENTAL
SYNTHESIS  AND THERAPEUTIC  EVALUATION  OF  4-ARYL-5-
CARBOXYMETHYL-6-CYCLOPROPYL-3,4-DIHYDROPYRIMIDINE-2(1H)-
ONES.
(A) Synthesis of 5-Carboxy methyl-6-cyclopropyl-4-phenyl-3,4-dihydropyrimidine-
2(1H)-ones.
A mixture of urea (0.60gm, 0.01 mol), benzaldehyde (1.06gm, 0.01 mol) and
methyl-3-cyclopropyl-3-oxo-propanoate (1.42gm, 0.01 mol) in 15 ml of ethanol
containing few drops of concentrated hydrochloric acid was refluxed for 8 hrs. The
solution was allowed to stand for 12 hrs. at room tempeture and the resulting solid mass
separated was filtered and crystallized from dioxane.Yield 45%, m.p. 110 0C, Anal.Calcd.
for C15H16 N2O3, Calcd: C, 66.16; H,5.92; N,10.29%, Found:  C, 66.34; H, 6.10; N,
10.48%.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 4-Aryl-5-carboxy methyl-6-cyclopropyl-3,4-dihydropyrimidines-
2(1H)-ones. were prepared. The physical data are recorded in Table No. 1.
(B) Antimicrobial activity of 4-Aryl-5-carboxymethyl-6-cyclopropyl-3,4-
dihydropyrimidine-2(1H)-ones.
All the compounds have been evaluated for antibacterial and antifungal activity
as described under.
ANTIMICROBIAL  ACTIVITY
It was carried out by cup-plate104 diffusion method which has been
described as under.
(a) Antibacterial activity:
The purified products were screened for their antibacterial activity using
cup-plate agar diffusion method. The nutrient agar broth prepared by the usual method
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was inoculated aseptically with 0.5 ml of 24 hrs. old subcultures of B. coccus,
S. aureus , Aerogenes, P.aeruginosa in separate  conical flasks at 35-400C and mixed
well by gentle shaking. About 25 ml content of the flask was poured and evenly spreaded
in a petridish (13 cm diameter) and allowed to set for 2 hrs. The cups (10 mm diameter)
were formed by the help of borer in agar medium and filled with 40mg solution of sample
in DMF).The plates were incubated at 370C for 24 hrs. and the control was also
maintained with 40μg solution of sample in DMF.The plates were incubated at 370C for
24 hrs and the control was of DMF in a similar manner and the zones of inhibition of the
bacterial growth were measured in millimeter and recorded in Graphical Chart No. 1.
(b) Antifungal activity:
Aspergillus niger was employed for testing antifungal activity using cup-plate
agar diffusion method. The culture was maintained on sabouraud’s agar slants. Sterilized
sabouraud’s agar medium was inoculated with 72 hr. old 0.5ml suspension of fungal
spores in a separate flask. About 25 ml of the inoculated medium was evenly spreaded
in a petridish (13cm diameter) and allowed to set for 2 hr. the cups (10mm diameter)
were punched. The plates were incubated at 30 0C for 48 hr. After the completion of
incubation period, the zone of inhibition of growth in the form of diameter in mm was
measure. Along the test solution in each petridish one cup was filled up with solvent,
which acts as control. The zone of inhibition of test solution  are recorded in Graphical
Chart No. 1.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (I)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
fluorophenyl, m-methoxyphenyl, m-nitrophenyl substituents against B.coccus. The
significant activity was observed in compounds bearing R= p-fluorophenyl, o-nitrophenyl
against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-fluoro
phenyl, p-chlorophenyl against Aerogenes. In the case of P.aeruginosa all the
compounds were least active except R= o-chlorophenyl, o-nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=p-fluorophenyl, m-
nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYLAMIDO-6-
CYCLOPROPYL-4-(p-METHOXY-PHENYL)-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONES.
Pyrimidine derivatives have been reported to possess various pharmacological
activities like antibacterial, antifungal, insecticidal etc. In order to achieve better drug
potency, we have synthesise pyrimidine derivatives of type (II) by the condensation of
N-Aryl-3-cyclopropyl-3-oxo-propanamide, urea and p-methoxy benzaldehydes in the
presence of catalytic amount of con. HCl.
NH
N
H
O
NH
R
O
O
CH3
               Type (II)         R=Aryl
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
O
OMe
O
+
O
O
NHR+
Toluene
R= Aryl
NH
N
H
O
O
NH
R
O
CH3
O
O
CH3
R
NH2
+
NH2 NH2
O
Methanol Hydrochloric acid
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IR SPECTRAL STUDIES OF 5-AMIDO-(p-CHLOROPHENYL)-6-CYCLOPROPYL-4-
(p-METHOXYPHENYL)-3,4-DIHYDROPYRIMIDINE-2(1H)-ONES.
Alkane C – H str.(asym.)                     3004 2975-2950 102
–CH3 C – H str. (sym.)                       2948 2880-2860 "
C – H def. (asym.)                    1456 1470-1435 "
 –C–CH2 C – H def.                                 1367 1385-1365 "
 Aromatic C – H str.                                  3026 3090-3030 "
C = C str                                   1541 1612-1550 "
                                                 1456 1580-1450 "
C – H i.p. (def)                         1149 1177-1027 "
C – H o.o.p. (def)                       833 832-802 "
Pyrimidine C = C str.                                   1487 1580-1520 103
N – H str.                                   3274 3440-300 "
C = O str.                                   1668 1660-1700 "
                                             Overlapped
Carboxamide C =O                                          1685 1680-1620 "
                               N – H str.                                   3143 3380-3150 "
 Halide                    C-Cl                                                     648                                   800-600                    "
    Ether       Ar-O-C                   1236                       1260-1200                   "
                  1027           1100-1000                   "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
NH
N
H
O
NH
O
O
CH3
Cl
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Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons Inference
1. 2.07-2.64               m              4H HC–(CH
2
)
2
2. 3.5-3.59               m              1H                          (H
2
C)
2
–CH
3. 3.74-3.75              s              3H -OCH
3
4. 5.47             s              1H Pyrm-CH
5. 6.81-7.50              m              8H Ar-H
6.             s              1H N–H
        (Overlapped)
7. 8.61            s              1H N–H
8. 9.37            s              1H N–H
Internal Standard : TMS; Solvent : DMSO : Instrument : BRUKER Spectrometer (400 MHz)
NMR SPECTRAL STUDIES OF 5-AMIDO-(p-CHLOROPHENYL)-6-CYCLOPROPYL-4-
(p-METHOXYPHENYL)-3,4-DIHYDROPYRIMIDINE-2(1H)-ONES.
NH
N
H
O
NH
O
O
CH3
Cl
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYLAMIDO-6-
CYCLOPROPYL-4-(p-METHOXYPHENYL)-3,4-DIHYDROPYRIMIDINE-
2(1H)-ONES.
(A) Synthesis of  N-(p-Chlorophenyl)-3-cyclopropyl-3-oxo-propanamide
A mixture of Methyl-3- cyclopropyl-3-oxo-propanoate (1.42 gm, 0.01 mol) and
p-chloroaniline (1.27 gm, 0.01 mol) in toluene was refluxed for 12 hr. Methanol was
removed using Dean & Stark azeotropic assembly. The mixture was cooled to room
temperatur and washed the reaction mixture with dil HCl and than washed with water.
Distilled out toluene under vaccume. The resulting rasidue was crystalized into the n-
Hexane. Yield 80 %, m. p. 1100C
TLC System : Ethyl acetate : Hexane (2 : 3)
(B) Synthesis of 5-(p-chlorophenyl)amido-6-cyclopropyl-4-(p-methoxyphenyl)
-3,4-dihydropyrimidine-2(1H)-ones.
A mixture of urea (0.60 gm, 0.01 mol), p-methoxybenzaldehyde (1.36 gm,
0.01 mol) and N-(p-chlorophenyl)-3-cyclopropyl-3-oxo-propanamide (2.37 gm,
0.01 mol) in 15 ml of methanol containing few drops of concentrated hydrochloric acid
was refluxed for 8 hrs. The solution was allowed to stand for 12 hrs. at room tempeture
and the resulting solid mass separated was filtered and crystallized from dioxane.Yield
42%, m.p.195 0C, Anal.Calcd. for C21H20N3O3Cl   Calcd: C, 63.40; H, 5.07; N, 10.56
%, Found:  C, 63.64; H, 5.35; N, 10.80 %.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 5-Arylamido-6-cyclopropyl-4-(p-methoxyphenyl)-3,4-dihydro
pyrimidine-2(1H)-ones were prepared. The physical data are recorded in Table No. 2.
(C) Biological evaluation of 5-Arylamido-6-cyclopropyl-4-(p-methoxyphenyl)-
3,4-dihydropyrimidine-2(1H)-ones.
Antimicrobial testing were carried out as described in Chapter-1 Section-1,(B),
Page No.39.The zones of inhibition of test solutions are recorded in Graphical Chart No.2.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (II)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=m,p-
dichlorophenyl, p-fluorophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= m-chlorophenyl, p-fluorophenyl, p-methoxyphenyl
against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-chloro
phenyl, m-methylphenyl,p-fluorophenyl against Aerogenes. In the case of P.aeruginosa
all the compounds were least active except R= p-chlorophenyl, p-fluorophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=m,p-dichlorophenyl,
m-methylphenyl and p-nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION - III
SYNTHESIS AND THERAPEUTIC EVALUATION OF  4-ARYL-5-CARBOXY
M E T H Y L - 6 - C Y C L O P R O P Y L - 3 , 4 - DIHYDROPYRIMIDINE-2(1H) -
THIONES.
Compounds containing thio pyrimidine ring are widely distributed in nature.
Many of these derivatives are reported to possess different biological activities such as
anticancer, calcium channel blockers, diuretics, antitubercular, spermicidal etc. These
valid observation led us to synthesise pyrimidine thiones of type (III) which have been synthe-
sized by the condensation of Methyl-3- cyclopropyl-3-oxo-propanoate,thiourea and
aryl benzaldehydes in the presence of catalytic amount of con.HCl.
NH
N
H
S
R
O
O
CH3
 Type (III)                R=Aryl
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
O
OMe
O
+
R= Aryl
NH
N
H
S
O
O
R
CH3
R
O
+
NH2 NH2
S
Hydrochloric acidEthanol
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IR SPECTRAL STUDIES OF 5-CARBOXY METHYL-6-CYCLOPROPYL-4-PHENYL-3,4-
DIHYDROPYRIMIDINE-2(1H)-THIONES.
Alkane C – H str.(asym.) 2922.9 2975-2950 102
–CH3 C – H str. (sym.) 2852.5 2880-2860 "
C – H def. (asym.)                       1448.4 1470-1435 "
 –C–CH2 C – H def.                                    1360.7 1385-1365 "
 Aromatic C – H str.                                     3093.6 3090-3030 "
C = C str                                      1596.9 1612-1550 "
                                                    1527.7 1580-1450 "
C – H i.p. (def)                            1156.2 1177-1027 "
C – H o.o.p. (def)                         819.7 832-802 "
Pyrimidine C = C str. 1559.3 1580-1520 103
C = S str. 1235.0 1100-1300 "
N – H str. 3310.6 3440-3300 "
Ester C =O                                            1702.6 1730-1700 "
C –O –C                                                1217.0 1260-1200 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
NH
N
H
O
O
S
CH3
     57
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons
Inference
1.        1.19-1.24                          m               4H HC–(CH
2
)
2
2.       3.11-3.18                         m               1H (H
2
C)
2
–CH
3.       3.57-3.60                        s               3H -OCH
3
4.       5.26-5.27                       s               1H Pyrm-CH
5.       7.09-7.67                      m               5H                                Ar-H
6.       8.55                     s               1H N–H
7.      9.47                    s               1H N–H
Internal Standard : TMS; Solvent : DMSO : Instrument : BRUKER Spectrometer (400 MHz)
NMR SPECTRAL STUDIES OF  5-CARBOXY METHYL-6-CYCLOPROPYL-4-PHENYL-3,4-
DIHYDROPYRIMIDINE-2(1H)-THIONES.
NH
N
H
O
O
S
CH3
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF  4-ARYL-5-CARBOXY
M E T H Y L - 6 - C Y C L O P R O P Y L - 3 , 4 - DIHYDROPYRIMIDINE-2(1H) -
THIONES.
(A) Synthesis of 5-Carboxy methyl-6-cyclopropyl-4-phenyl-3,4-dihydro-
pyrimidine-2(1H)-thiones.
A mixture of thiourea (0.76gm, 0.01 mol), benzaldehyde (1.06 gm, 0.01 mol)
and methyl-3- cyclopropyl-3-oxo-propanoate (1.42 gm, 0.01mol) in 15 ml of ethanol
containing few drops of concentrated hydrochloric acid was refluxed for 8 hrs. The
solution was allowed to stand for 12 hrs. at room tempeture and the resulting solid mass
separated was filtered and crystallized from dioxane.Yield 48%, m.p.172 0C, Anal.Calcd.
for C 15 H16N2O2S,  Calcd: C, 62.48; H,5.59; N,9.71%, Found: C,62.58; H,5.68; N,
9.97 %.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 4-Aryl-5-carboxy methyl-6-cyclopropyl-3,4-dihydropyrimidine-
2(1H)-thions were prepared. The physical data are recorded in Table No. 3.
(B) Biological evaluation of 4-Aryl-5-carboxy methyl-6-cyclopropyl-3,4-
dihydropyrimidine-2(1H)-thiones.
Antimicrobial testing were carried out as described in Chapter-1, Section-1(B),
Page No.39.The zones of inhibition of test solutions are recorded in Graphical Chart
No.3.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (III)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
fluorophenyl, p-methylphenyl,m-notrophenyl substituents against B.coccus. The significant
activity was observed in compounds bearing R= m-nitrophenyl, p-fluorophenyl, against
S.aureus.
The maximum activity was displayed by the compounds bearing R= o-chloro
phenyl, o-nitrophenyl against Aerogenes. In the case of P.aeruginosa all the compounds
were least active except R= p-chlorophenyl, o-nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R= m-methoxyphenyl against
A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-IV
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5- ARYLAMIDO-6-
CYCLOPROPYL-4-(p-METHOXY PHENYL)-3 ,4-DIHYDROPYRIMIDINE-
2(1H)-THIONES.
Compounds containing pyrimidine ring are widely distributed in nature. Many of
these derivatives are reported to possess different biological activities. In view of these
report, we have synthesized 5-Arylamido-6-cyclopropyl-4-(p-methoxyphenyl)-3,4-
dihydropyrimidine-2(1H)-thiones of type (IV) by the condensation of N-Aryl-3-
cyclopropyl-3-oxo-propanamide, thiourea and p-methoxybenzaldehyde in the presence
of catalytic  amount of con. HCl.
NH
N
H
S
NH
R
O
O
CH3
      Type (IV)                           R=Aryl
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
O
OMe
O
+
O
O
NHR+
Toluene
R= Aryl
NH
N
H
S
O
NH
R
O
CH3
O
O
CH3
R
NH2
+
NH2 NH2
S
Hydrochloric acidEthanol
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IR SPECTRAL STUDIES OF 5-AMIDO-(p-CHLOROPHENYL)-6-CYCLOPROPYL-4-
(p-METHOXYPHENYL)-3,4-DIHYDROPYRIMIDINE-2(1H)-THIONES.
Alkane C – H str.(asym.) 2958.6 2975-2950 102
–CH3 C – H str. (sym.) 2867.0 2880-2860 "
C – H def. (asym.)                       1424.3 1470-1435 "
 –C–CH2 C – H def.                                    1397.0 1385-1365 "
 Aromatic C – H str.                                     3079.0 3090-3030 "
C = C str                                      1582.0 1612-1550 "
                                                    1474.4 1580-1450 "
C – H i.p. (def)                            1174.6 1177-1027 "
C – H o.o.p. (def)                          811.0 832-802 "
Pyrimidine C = C str. 1497.0 1580-1520 103
C = S str. 1240.0 1300-1100 "
N – H str. 3398.3 3440-3300 "
Carboxamide C =O                                            1683.1 1680-1620 "
                               N – H str.                                     3235.4 3380-3150 "
 Halide                    C-Cl                                                      745.4                            800-600 "
    Ether       Ar-O-C        1213.1             1260-1200      "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
NH
N
H
O
NH
S
O
CH3
Cl
     67
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons Inference
1. 0.51-1.02                 m              4H                       HC–(CH
2
)
2
2. 1.79-1.99                m              1H                       (H
2
C)
2
–CH
3. 3.34                s              3H                            -OCH
3
4. 5.14-5.37                s              1H                          Pyrm-CH
5. 6.81-7.74                m              8H                            Ar-H
6. 9.38               s              1H                            N–H
7. 9.78              s              1H                            N–H
Internal Standard : TMS; Solvent : DMSO : Instrument : BRUKER Spectrometer (300 MHz)
NMR SPECTRAL STUDIES OF 5-AMIDO-(p-CHLOROPHENYL)-6-CYCLOPROPYL-4-
(p-METHOXYPHENYL)-3,4-DIHYDROPYRIMIDINE-2(1H)-THIONES.
NH
N
H
O
NH
S
O
CH3
Cl
      8.   9.90   s               1H                                    N–H
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5- ARYLAMIDO-6-
CYCLOPROPYL-4-(p-METHOXY PHENYL)-3 ,4-DIHYDROPYRIMIDINE-
2(1H)-THIONES.
(A) Synthesis of  N-(p-Chlorophenyl)-3-cyclopropyl-3-oxo-propanamide
   See Chapter-1, Section II (A), Page No.50.
(B) S y n t h e s i s  o f   5 - ( p - Ch l o r o p h e n y l ) amido- 6 - c y c l o p r o p y l - 4 -
( p- m e t h o x y phenyl)-3,4-dihydropyrimidine-2(1H)-thiones.
A mixture of thiourea (0.72 gm, 0.01 mol), p-Methoxybenzaldehyde (1.36 gm,
0.01 mol) and N-(p-Chlorophenyl)-3-cyclopropyl-3-oxo-propanamide (2.37 gm, 0.01
mol) in 15 ml of ethanol containing few drops of concentrated hydrochloric acid was
refluxed for 8 hrs. The solution was allowed to stand for 12 hrs. at room tempeture and
the resulting solid mass separated was filtered and crystallized from dioxane.Yield 60%,
m.p.160 0C, Anal.Calcd. for C21H20N3O2S Cl  Calcd: C, 60.94; H, 4.87; N, 10.15 %,
Found:  C, 61.12; H, 5.07; N, 10.38 %.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 5 - Arylamido-6-cyclopropyl-4-(p-methoxyphenyl)-3,4-
dihydropyrimidine-2(1H)-thiones were prepared. The physical data are recorded in Table
No.4.
(C) Biological evaluation of 5-Arylamido-6-cyclopropyl-4-(p-methoxyphenyl)-
3,4-dihydropyrimidine-2(1H)-thiones.
Antimicrobial testing were carried out as described in Chapter-1, Section-1(B),
Page No.39.The zones of inhibition of test solutions are recorded in Graphical Chart
No.4.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (IV)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=m-
methylphenyl, p-methylphenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R=  p-fluorophenyl, p-methoxyphenyl  against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-chloro
phenyl, p-methylphenyl against Aerogenes. In the case of P.aeruginosa all the
compounds were least active except R= p-methoxyphenyl, p-fluorophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R= m-chlorophenyl, p-
methoxyphenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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INTRODUCTION
The pyrazole ring system (I) consists of a doubly unsaturated five membered
ring containing two adjacent nitrogen atoms. Knorr1,2 first synthesised a compound
containing this system in 1883 by a reaction of ethylacetoacetate with phenylhydrazine
which yield 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (II).
N
N
R3R2
R1
R
N
H
N N
N
Ph
O
CH3
     (I)                                  (II)                                      (III)
Pyrazoles and their reduced forms pyrazolines are well known nitrogen containing
five membered heterocyclic compounds (III) which possess widespread chemical and
pharmacological applications3-5 such as analgesic, antipyretic, and antirheumatic
activities.6,7 These derivatives are also well known for their pronounced anti-inflammatory
properties8,9  and are used as potent antidiabetic agents.10,11 In addition, the
pharmacological and antitumor activities of many compounds containing pyrazoline rings
have been reviewed.12-14Pyrazolines can  be synthesized from α,β-unsaturated carbonyl
compounds and hydrazines. They are reported to be potential extractants and powerful
drugs.15 The chemistry of pyrazoline was reviewed by Jorbe in 1967, which have been
studied extensively for their biodynamic behaviour16 and industrial applications.17
SYNTHETIC ASPECTS
Different methods are reported in literature for the preparation of pyrazolone are
as under.
1. By the reaction of ethyl acetoacetate with hydrazines.18-20
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2. By the reaction of methyl esters of alkylacetylenecarboxylic acids with
alkylhydrazines. this appears to be 1,3-dialkyl-5-pyrazolone.21-24
R2C
COOMe
+ NH2 NH
R1
N
N OH
R2
R1
N
N O
R2
R1
methanol
3. Knorr L.25 has synthesised two structrually isomeric pyrazoles by the
condensation of substituted hydrazines with 1,3-dicarbonyl compounds.
R
R2
O
O
R1 NH2 NH
Ar
+ N
N
R2
R1
R
Ar
N
N
R1
R2
R
Ar
+ + H2O
4. Pechmann H. V.26 has synthesised pyrazoles by the reaction of acetylenes
and diazomethane.
CH CH + CH2 N+ N-
N
H
N
5. Perumal P.T. et.al.27 have synthesised pyrazoles by the reaction of hydrazones
with Vilsmeier reagent.
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CO2CH2C6H5
H5C6
N NH
C6H3(NO2)2
DMF-POCl3
70°-80°, 4h
NN
H5C6
CO2CH2C6H5
C6H3(NO2)2
6. By the microwave assisted cyclocondensation of hydrazine derivatives with
alkyl dihalides28.
NH
NH2R
+ X X K2CO3, H2OMW N
N
R
7.  Boruah R.C.et  al .29 suggested one pot synthesis of pyrazoles from β-
Formylenamides.
R1
NHAcOHC
R2
NH2OH, HCl
KH2PO4 N
N Ac
R1R2
8. Marica Theiszova et al.30 have synthesised pyrazoles by condensation
of 2-ethoxymethylene-3-oxobutanenitrile and hydrazines.
9. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with
hydrazine hydrate.31
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N
H
NR
R1
R
O
R1
+ NH2.NH2.H2O
10. 2-Pyrazolines can be prepared by condensation of chalcone dibromide with
hydrazines.32
11. Epoxidation of chalcones gave epoxy ketones which reacts with hydrazine
and phenyl hydrazine to give pyrazolines.33
12. 2-Pyrazolines can be prepared by cyclocondensation of γ-ketosulfone with
refluxing hydrazines and KOH/methanol under nitrogen condition.34
S
O O
O
R1
NH2 NH R
KOH  methanol
reflux N2
N
N
R
13. Dipolar cycloaddition of nitrileimines of dimethyl fumarate, fumaronitrile
and the N-aryl maleimides yielded the corresponding pyrazolines.35
14. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine
hydrate and phenyl hydrazine to give pyrazolines.36
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REACTION MECHANISM
The mechanism of the formation of pyrazolone is illustrated as under37
R
OO
O
R1
R
OHO
O
R1
R
OH2
O
O
R1
H+
NH2 NH
R2
..
R
NHO
O
R1
NH
R2
..
R
NHO-
OR1
N
R2
R
NHO
N
R2
+
The following mechanism seems to be operable for the condensation of chalcones
with hydrazines.38
R
O
R1 NH2-NH-R2
R
C
O
CH-
CH R1
NH +
R2
NH2
(II)(I)
Proton transfer
R
C+
OH
CH-
CH R1
N
R2
NH2
R
C
O
CH2
CH R1
N
R2
NH2
(III)
R
COH
CH2
CH R1
N
R2
NH
(IV)
-H2OR C
CH2
CH R1
N
R2
N
(V)
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Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system (I) forms species (II), in which the negative charge is mainly accommodated by
the electronegative oxygen atom. Proton transfer from the nitrogen to oxygen produces
an intermediate end which simultaneously ketonises to ketoamine (III). Another
intramolecular nucleophillic attack by the primary amino group of ketoamine on its
carbonyl carbon followed by proton transfer from nitrogen to oxygen leads  ultimately
to hydroxyl amine (IV). The later with a hydroxy group and amine group on the same
carbon loses water easily to yield the pyrazolines(V).
THERAPEUTIC  IMPORTANCE
Antipyrine, 2,3-dimethyl-1-phenyl-3-pyrazolin-5-one was the first pyrazolone
derivative used in the management of pain and inflammation. Research devoted to the
development of new analgesic agents of this series led to the discovery of aminopyrine
and dipyrone.In an effort to increase analgesic properties and decrease adverse effects
pyrazolidinedione derivatives, phenylbutazone and its potent metabolite oxyphenbutazone
were synthesized.The synthesis and therapeutical studies of pyrazolones and their
derivatives were undertaken by several groups of workers.39-43
Pyrazolone derivatives exhibit broad band spectrum of therapeutic activities. The
several biological activities associated with pyrazolone have been described as under
1. Antitumer.44
2. Antiulcer.45
3. Antibacterial.46
4. Anticancer.47
5. Neurotonsin receptor antagonist.48
6. Lipoxygenase inhibitor.49
7. Parasitical.50
8. Antiinflammatory.51
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9. Antitubercular.52
10. Antidiabetics.53,54
11. Immunosuppressive.55
12. A1 and A2 adrenosine Binding Activities.
56
13. leukotriene inhibitors.57
14. cardiac disorder.58
15. coagualtion factor.59
16. antiinfective.60
17. organ transplantation.61
18. antibiotics.62
Nakamura K. et al.63 have synthesised some pyrazolone derivatives and found
to be Cox-II inhibiting agents useful for the treatment and prevention of inflammatory
conditions, collagen diseases, antiimmune disease, thrombosis and cancer or neuro
degenerative diseases.
Yoshikuni et al.64and Bratusek et al.65 have synthesised 3-methyl-5-oxopyrazole
derivatives of type (II) and (III) respectively and evaluated their biological activity.
(II)                                                                                                                 (III)
Nakatshuka M. et al.66 have assessed pyrazolone as immuno suppressants. Banks
B. J. et al.67 have prepared pyrazolone derivatives which were active as antiparasitic
agents.
N
N
O
Ph
O
O
N
N
O
CH3
Ph
O
NH
N
N
H
O
CH3
CH3
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Salman, A.S.S. et al.68have prepared some novel pyrazolone derivative (IV) which
showed antimicrobial activity. Sharma V. and Khan, M. S. Y. et al.69 have synthesized
pyrazolone derivative (V) which were found to active as non- steroidal antiinflammatory
drug.
CH3
CH3
CH3
N
O
NH
O
O
(IV) (V)
NH
N
N
N
O
CH3
N
S
O
Cl
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SOME DRUGS MOLECULES WHICH  ARE CURRENTLY  USED IN MARKET
N
NO
CH3
CH3 N
NO
CH3
CH3
NH2
N
NO
CH3
CH3
NH
CH3
CH3
N
NO
CH3
CH3
NH
O
N
CH3
CH3CH3
N
NO
CH3
CH3
CH3
CH3
N
NO
O
R
CH3
Antipyrine
Antiinflammtory/Antipyretic
Aminopyrine
Antipyretic
Isopyrine
Antipyretic
Aminopropylon
Antipyretic
Propylphenazone
Antipyretic
R=H Phenylbutazone/Antipyretic
R=OH Oxyphenbutazone/ Antiarthritic,
       Antiinflammatory
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Tricyclic structure containing pyrazole moiety and pyrazoloquinolin-3-one have
been synthesised to evaluate their GABAA-benzodiazepine receptor affinities70.Some
of the pyrazolepyrimidines or pyrazolopyridines are currently under clinical
development71. Pyrazolepyrimidines (I) have been also studied for their antagonistic
properties for the corticotropin releasing factor (CFR-1) receptor whose activation is
related to depression and anxiety72.
In search of new class of neuroleptic drugs, pyrazolo[1,5-a]pyridine (II) have
been evaluated for presynaptic dopamine autoreceptor agonist activity.73
N
N
N
N
BuEt
CH3
R
Ar
N N
N RR1
                                                    (I)                                                 (II)
Pyrazolylpiperidine (III) and a series of structural analogs have been identified
as novel and selective human D4 receptor antagonists.74,75
Cl
NH N
N
                                                        (III)
Recently, 1H-pyrazol-1-carboxamidines have been shown to be competitive
inhibitors of all three isoforms, the most selective compound, 1H-pyrazole-N-(3- amino
methylanilino)-1-carboxamidine, was 100-fold selective for neuronal NOS over
endothelial NOS.76
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Novel analogues of linezolid (XV) were synthesised by Stan D.Andrea,et. al.77
and evaluated their antibacterial activity.
Rajendra Prasad Y.et al.78have synthesised some 1,3,5-triphenyl-2-pyrazolines
and 3-(2’-hydroxy naphthalen-1’-yl)-1,5-diphenyl-2-pyrazolines and reported as
antidepressant (XVI) & (XVII).
 (XVI)  (XVII)
N N
R1
R2
R3
R4
 R1, R2, R3, R4 = Alkyl
N
N N
O
O
F
NH
Ac
(XV)
1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines (XVIII) were
synthesized by Gulberk Ucar et al.79 A novel cholinesterase and selective monoamine
oxidase B inhibitors for the treatment of Parkinson’s and Alzheimer’s diseases.
N N
R2
R3
OH
R1
R4
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NN
S
NH
S
R
R1
(XVIII)
Fedele Manna.80 and co workers synthesized a series of substituted pyrazolines
(XIX) and evaluated for their anticancer activity and for their ability to inhibit
P-glycoprotein mediated multidrug resistance by direct binding to a purified protein
domain containing an ATP-binding site and a modulator interacting region.
N
N
O
CH3
O
CH3
Jones D. G. et al.81 have synthesised pyrazoline derivatives (XX) which passesing
PR antagonist.Amir Azam and co-workers82 have synthesised some 1-N-Substituted
thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives (XXI) and tested their antiamoebic
activity.
(XIX)
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N
N
S
O
O
Cl
N
CH3
CH3
Cl Cl
(XX)
N
N
S R
R=Cyclic amine(XXI)
Mohammad Abid and Amir Azam83 have synthesized 1-(thiazolo[4,5-
b]quinoxaline-2-yl)-3-phenyl-2-pyrazoline derivatives (XXII) and reported as
antiamoebic agent. Goodell. et al.84 have synthesized some newer 1,3,5-trisubstituted
pyrazoline derivatives which shows anti west nile virus activity (XXIII).
N
N
S
N
N
NCH3
Cl
Abd El-Galil E.Amr et al.85 synthesized A series of androstano[17,16c]pyrazolines
(XXIV).The compounds were evaluated for their antiandrogenic activity compared to
that of Cyproterone.
NN
CH3
CH3
H
H
H
H
CH3 R
CH3
H Ar
(XXIV)
N
NS
O
NO2
Cl
                           (XXII)                                                       (XXIII)
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A novel pyrazoline (XXVII)compound that has potent cerebroprotective effects
in the rat focal cerebral ischemia model was descoverd by. H. Kawazural et al.86 David
M. Ferguson, and Pei-Yong Shi.87 synthesize Triaryl pyrazoline [5-(4-chloro-phenyl)-3-
thiophen-2-yl-4,5-dihydro-pyrazol-1-yl]-phenyl-methanone (XXVIII) inhibits flavivirus
infection in cell culture. The inhibitor was identified through high-throughput screening
of a compound library using a luciferase-expressing West Nile (WN) virus infection assay.
(XXVII) (XXVIII)
N
NCH3
N O
N N
O
S
Cl
(XXVI)
Drug molecules having pyrazole nucleus with good pharmacological activities are
listed below.
NN
H
O
P
P
EtO
EtO
O
O
EtO
EtO
F
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Zaleplon        [Diabetic agent]
                       [Sedative,Hypnotic]
Celecoxib PNU-32945
   [Antiinflammatory] [HIV-1 Reverse trascriptase
          inhibitors]
N
N
O
O
H3C(H2C)3
N
N
H
H
H H
CH3
CH3 H
CH3 CH3
      Zonipiride         Oxyphenbutazone
        [Sodium ion exchanger]              [Antiarthritic]
NN
N
O
N
NH2 NH2
N
N
N
N
Ar
N
N
Stanozolol
            [Insecticide]
 [Antitumor agent]
N
N
NHN
+C-
N
O
CH3
CH3
N
N
O
N
CH3
CH3
CF3
N
N
CF3
CH3H2NO2S
N
N
CH3NC
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With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of pyrazoles which have been  described in
following sections
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
2-N-SUBSTITUTED 5-CYCLOPROPYL-2,3-DIHYDRO-
PYRAZOLE-3-ONES.
SECTION - II : SYNTHESIS AND THERAPEUTIC EVALUATION OF
N-ARYL-3-(o-CHLOROPHENYL)-2-(CYCLOPROPYL-
CARBONYL)-ACRYLAMIDES.
SECTION - III : SYNTHESIS AND THERAPEUTIC EVALUATION OF
4-ARYLAMIDO-5-(o-CHLOROPHENYL)-3-CYCLOPROPYL
-4,5-DIHYDRO-1H-PYRAZOLES.
SECTION - IV : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1-N-ACETYL-4-ARYLAMIDO-3-CYCLOPROPYL-5-
     (o-CHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOLES.
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-N-SUBSTITUTED 5-
CYCLOPROPYL-2,3-DIHYDROPYRAZOLE-3-ONES.
Pyrazole derivatives  play a vital role showing of their wide range of biologi-
cal activity and with an aim to getting better drug, it was considered worth while to synthe-
size some new  pyrazole derivatives of Type (V) which have been synthesized by the
condensation of  Methyl-3- cyclopropyl-3-oxo-propanoate and hydrazine in the pres-
ence of gla. acetic acid.
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry.Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
N NH
O
R
  Type (V)                   R= H / Aryl
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REACTION SCHEME
O
OMe
O
+ NH
NH2
R
N
NH
R
O
gla. acetic acid
R= H, Aryl
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Alkane C – H str.(asym.)          3009.3 2975-2950 88
C – H def. (asym.)                       1453.4 1470-1435 "
 –C–CH2 C – H def.                                    1349.3 1385-1365 "
 Aromatic C – H str.                                     3090.2 3090-3030 "
C = C str                                      1536.6 1612-1550 "
                                                    1486.9 1580-1450 "
C – H i.p. (def)                            1175.4 1177-1027 "
C – H o.o.p. (def)                          837.4 832-802 "
Pyrazoline C = N str.                                     1592.6 1630-1580 90
C – N str.                                     1307.7 1300-1200 "
NC =O                                          1736.9 1750-1700 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
N
NH
O
IR  SPECTRAL STUDIES OF  5-CYCLOPROPYL-2-N-PHENYL-2,3-DIHYDROPYRAZOLE-3-
ONE.
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NMR SPECTRAL STUDIES OF  5-CYCLOPROPYL-2-N-PHENYL-2,3-DIHYDROPYRAZOLE-3-
ONE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : GEMINI-2000 Spectrometer (200 MHz)
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons
1. 0.87-1.02                  m              4H                       HC–(CH2)2
2. 1.74-1.90                  m              1H                      (H2C)2–CH
3. 5.22                 s              1H                        pyrz–CH
4. 7.15-7.83                 m              5H                           Ar-H
5. 11.44                 s              1H                            N-H
Inference
N
NHO
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N
N
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N
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O
m
/z
 =
 1
73
N
N
H
-
C
H
2
m
/z
 =
 1
48
N
+
N
m
/z
 =
 1
31
N
N
H
-
C
H m
/z
 =
 1
20
N
N
H
m
/z
 =
 1
06
o+
o+
o+
o+
o+
( B
as
e 
P
ea
k)
     103
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-N-S U B S T I T U T E D
5-CYCLOPROPYL-2,3-DIHYDROPYRAZOLE-3-ONES.
(A) Synthesis of  5-Cyclopropyl-2-phenyl-2,3-dihydropyrazole-3-one.
Take  mixture of methyl -3- Cyclopropyl-3-oxo-propanoate (1.42 gm, 0.01 mol)
and phenyl hydrazine (1.08gm, 0.01mol) into the methanol, add glacial acetic acid 2-5
drops to the reaction mixture and heat the reaction mass at 70-80oC for 1hr. cool and
pour on the ice, filter the product and washed with water dry and recrystalized from
isopropyl alcohol .Yield 62 %  m.p. 200oC. Anal.Calcd. for    C12H12N2O  Calcd: C,
71.98; H, 6.09; N, 13.99 %, Found: C, 71.10; H, 6.15; N, 14.20%.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 2-N-Subs t i tu ted  5 -cyc lopropy l -2,3-d ihydropyrazole-3-
ones were prepared. The physical data are recorded in Table No. 5.
(B) Bio log ica l evaluation of 2-N-Su b s t i t u t e d  5 - c y c l o p r o p y l - 2,3-
d ihydropyrazole-3-ones.
Antimicrobial testing were carried out as described in Chapter-1,Section-1(B),
Page No.39.The zones of inhibition of test solutions are recorded in Graphical Chart
No.5.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (V)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=m,p-
dichlorophenyl, p-nitrophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= p-chlorophenyl, p-fluorophenyl, p-methoxyphenyl
against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-nitro phenyl,
p-methylphenyl against Aerogenes. In the case of P.aeruginosa all the compounds were
least active except R= m-chlorophenyl, o-nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=p-fluorophenyl, p-
methoxyphenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-II
The broad spectrums of pharmacological properties have been demonstrated by
the arylidine  nucleus.Inspired by these facts, novel arylidine derivatives of type (VI)
have been synthesized by the condensation of  N-Aryl-3-cyclopropyl-3-oxo-
propanamide with o-chloro benzaldehyde in the presence of piperidine.
SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-3-(o -
CHLOROPHENYL)-2-(CYCLOPROPYLCARBONYL)-ACRYLAMIDES.
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
O
O
NH
Cl
R
  Type (VI)                          R=Aryl
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REACTION SCHEME
O
OMe
O
+
O
O
NHR +
Toluene
O
O
NH
R
Cl
Toluene
R= Aryl
O
Cl
R
NH2
Piperidine
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Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2990 2975-2950 88
–CH3 C – H str. (sym.) 2830 2880-2860 "
C – H def. (asym.)                          1464 1470-1435 "
 –C–CH2 C – H def.                                       1398 1385-1365 "
 Aromatic C – H str.                                        3083 3090-3030 "
C = C str                                         1553 1612-1550 "
                                                       1511 1580-1450 "
C – H i.p. (def)                               1178 1177-1027 "
C – H o.o.p. (def)                             829 832-802 "
Carboxamide C =O                                               1635 1680-1620 89-90
N – H str.                                        3272 3380-3150 "
Carbonyl C=O                                               1672 1760-1650 "
     Halide          C-Cl             761                               800-600      "
    Ether         Ar-O-C           1243             1260-1200      "
          1033             1100-1000      "
IR SPECTRAL STUDIES OF 3-(o-CHLOROPHENYL)-2-(CYCLOPROPYLCARBONYL)-
N-(p-METHOXYPHENYL)-ACRYLAMIDE.
O
O
NH
Cl
O
CH3
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Internal Standard : TMS; Solvent : CDCl3  : Instrument : BRUKER Spectrometer (400 MHz)
Signal
No. Multiplicity
Signal Position
(δ ppm)
Relative No.
of Protons
1. 1.08-1.27                  m          4H                      HC–(CH2)2
2. 2.50-2.51                 m          1H                      (H2C)2–CH
3. 3.75-3.78                s          3H                          -OCH3
4. 7.99               s          1H                        Ar-C=CH
5. 6.82-7.65               m          8H                           Ar-H
6. 8.08               s          1H                           N-H
Inference
NMR SPECTRAL STUDIES OF  3-(o-CHLOROPHENYL)-2-(CYCLOPROPYLCARBONYL)-N-
(p’-METHOXYPHENYL)-ACRYLAMIDE.
O
O
NH
Cl
O
CH3
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL- 3-(o-
CHLOROPHENYL)-2-(CYCLOPROPYLCARBONYL)-ACRYLAMIDE.
(A) Synthesis of  3-Cyclopropyl-N-(p-methoxyphenyl)-3-oxopropanamide
See  Chapter-1, Section  II (A), Page No.50.
(B) S y n t h e s i s  o f  3 - ( o - Ch l o r o p h e n y l ) - 2 - ( c y c l o p r o p y l c a r b o n y l ) - N -
(p-methoxyphenyl)-acrylamide.
Reflux the mixture of 3-Cyclopropyl-N-(p-methoxyphenyl)-3-oxopropanamide
(2.33 gm, 0.01 mol) and o-chloro benzaldehyde (1.40gm, 0.01mol) with catalytical
amount of piperidine in 15 ml of toluene and water was removed using Dean & Stark
azeotropic assembly. The mixture was cooled to room  temperatur, then washed  with
sodium bisulphite solution. The layers were settled down,   organic layer was seperated.
It was further washed with water and seperateed layers. Excess of solvent was distilled
out  and the product was isolated,Yield 39%, m.p.820C. Anal.Calcd. for C20H18 NO3Cl
Calcd: C, 67.51 H,5.10; N,3.94%, Found: C, 67.75; H,5.19; N, 4.10 %.
TLC System : Ethyl acetate : Toluene (2 : 3).
Similarly, other N-Aryl-3-(o-chlorophenyl)-2-(cyclopropylcarbonyl)-acrylamide
were prepared. The physical data are recorded in Table No. 6.
(C) Biological evaluation of N-Aryl-3-(o-chlorophenyl)-2-(cyclopropyl-
carbonyl)-acrylamide.
Antimicrobial testing were carried out as described in Chapter-1, Section-1(B),
Page No.39.The zones of inhibition of test solutions are recorded in Graphical
Chart No.6.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (VI)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=m,p-
dichlorophenyl, p-chlorophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= m,p-dichlorophenyl, p-fluorophenyl, p-methylphenyl
against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-chloro
phenyl, m-methylphenyl,p-nitrophenyl against Aerogenes. In the case of P.aeruginosa
all the compounds were least active except R= m-nitrophenyl, p-fluorophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=m-chlorophenyl and p-
nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-III
SYNTHESIS AND THERAPEUTIC EVALUATION OF  4-ARYLAMIDO-5-
(o-CHLOROPHENYL)-3-CYCLOPROPYL-4,5-DIHYDRO-1H-PYRAZOLES.
Pyrazolines are endowed with various biological activities. Looking at
their versatile therapeutic importance and with an aim to getting better drug, it was
considered worthwhile to synthesized some new pyrazole of Type (VII) which have
b e e n  synthesized by the  condensat ion of  N-Aryl-3-(o -chlorophenyl)-2-
(cyclopropylcarbonyl)-acrylamide  with hydrazine hydrate in the presence of methanol.
       Type (VII)                 R=Aryl
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
Cl
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R
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IR SPECTRAL STUDIES OF 4-(p-METHOXYPHENYL)AMIDO-5-(o-CHLOROPHENYL)-3-
CYCLOPROPYL-4,5-DIHYDRO-1H-PYRAZOLE.
Alkane C – H str.(asym.) 2980 2975-2950 88
–CH3 C – H str. (sym.) 2800 2880-2860 "
C – H def. (asym.)                          1440 1470-1435 "
 –C–CH2 C – H def.                                       1350 1385-1365 "
 Aromatic C – H str.                                        3010 3090-3030 "
C = C str                                         1531 1612-1550 "
                                                       1513 1580-1450 "
C – H i.p. (def)                               1177 1177-1027 "
C – H o.o.p. (def)                             828 832-802 "
Pyrazoline C = N str.                                        1581 1630-1580 89-90
C – N str.                                        1301 1300-1200 "
N – H str.                                        3305 3440-3300 "
Carboxamide C =O                                               1656 1680-1620 "
N – H str.                                        3243 3380-3150 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
 Halide       C-Cl                          754                               800-600    "
Ether      Ar-O-C         1250        1260-1200                 "
        1033        1100-1000    "
NH
N
O
NH
HH
Cl
O
CH3
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Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (400 MHz)
Signal
No. Multiplicity
Signal Position
(δ ppm)
Relative No.
of Protons
1. 0.66-0.69               m               4H HC–(CH2)2
2. 1.18              m               1H (H2C)2–CH
3. 3.70-3.75             s               3H O-CH3
4. 4.74            d               1H pyrz–Ha
5. 5.46           d               1H pyrz–Hb
6. 6.74-7.66           m               8H Ar-H
7.          s               1H N–H
       (Overlapped)
8. 9.78          s               1H                                N–H
Inference
NMR SPECTRAL STUDIES OF 4-(p-METHOXYPHENYL)-AMIDO-5-(o-CHLOROPHENYL)-3-
CYCLOPROPYL-4,5-DIHYDRO-1H-PYRAZOLE.
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-ARYLAMIDO-5-(o-
CHLOROPHENYL)-3-CYCLOPROPYL-4,5-DIHYDRO-1H-PYRAZOLES.
(A) Synthesis of N-Aryl-3-cyclopropyl-3-oxo-propanamide.
           See  Chapter-1, Section  II (A), Page No.50.
(B) S y n t h e s i s  o f  3 - ( o - Ch l o r o p h e n y l ) - 2 - ( c y c l o p r o p y l c a r b o n y l ) - N -
(p-methoxyphenyl) acrylamide.
See  Chapter-2, Section II (B), Page No. 113.
(C) Synthesis of 4-(p-Methoxyphenyl)amido-5-(o-chlorophenyl)-3-cyclopropyl-
4,5-dihydro-1H-pyrazole.
A mixture of  3-(o-Chlorophenyl)-2-(cyclopropylcarbonyl)-N-(p-methoxyphenyl)
acrylamide(3.55gm 0.01mol) in methanol  (25 ml) and hydrazine hydrate (0.5gm, 0.01
mol) was heated on water bath at 70oC for 8 hrs.Cool the reaction mixture and pour into
the crushed ice. Filter the product and washed with water dry and recrystlized into the
isopropyl alcohol. Yield 50% m.p. 130oC  Anal.Calcd. for C20H20N3O2Cl Calcd: C,
64.95; H, 5.45; N, 11.36 %, Found: C, 65.21; H,5.65; N, 11.62 %.
TLC System : Ethyl acetate : Toluene (2 : 3).
Similarly, other 4-Arylamido-5-(o-chlorophenyl)-3-cyclopropyl-4,5-dihydro-
1H-pyrazoles were prepared. The physical data are recorded in Table No.7.
(D) Biological evaluation of  4-Arylamido-5-(o-chlorophenyl)-3-cyclopropyl-
4,5-dihydro-1H-pyrazoles.
Antimicrobial activity was carried out as described in Chapter-1, Section-1(B),
Page No. 39. The zone of inhibition of the test solutions are recorded in Graphical Chart
No.7.
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ZONE OF INHIBITION IN mm
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type
(VII) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=m,p-
dichlorophenyl, p-fluorophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= m-chlorophenyl, p-chlorophenyl, m-methylphenyl
against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-methyl
phenyl, m-methylphenyl,o-nitrophenyl against Aerogenes. In the case of P.aeruginosa
all the compounds were least active except R= p-chlorophenyl, p-fluorophenyl,4-
nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R= m,p-dichlorophenyl,
and o-nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-IV
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-N-ACETYL-4-
ARYLAMIDO-3-CYCLOPROPYL-5-(o-CHLOROPHENYL)-4,5-DIHYDRO-1H-
PYRAZOLES.
Pyrazolines consist one of the most active class of compounds possessing
diversified biological activities. Looking at their versatile therapeutic importance and
with an aim to getting better drug, it was contemplated to synthesise some new pyrazolines
(VIII) which have been synthesized by the condensation of N-Aryl- 3-(o-chlorophenyl)-
2-(cyclopropylcarbonyl)-acrylamide  with hydrazine hydrate in the presence of gla. acetic
acid.
Type (VIII)          R=Aryl
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further  supported  by Mass spectrometry. Purity of all compounds has been checked
by thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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IR SPECTRAL STUDIES OF 1-N- ACETYL-4-(p-METHOXYPHENYL)AMIDO-3-CYCLOPROPYL-
5-(o-CHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOLE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-450 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2980 2975-2950 88
–CH3 C – H str. (sym.) 2850 2880-2860 "
C – H def. (asym.)                          1468 1470-1435 "
 –C–CH2 C – H def.                                       1354 1385-1365 "
 Aromatic C – H str.                                        3089 3090-3030 "
C = C str                                         1551 1612-1550 "
                                                       1508 1580-1450 "
C – H i.p. (def)                               1165 1177-1027 "
C – H o.o.p. (def)                             832 832-802 "
Pyrazoline C = N str.                                        1623 1630-1580 89-90
C – N str.                                        1293 1300-1200 "
Carboxamide C =O                                               1623 1680-1620 "
N – H str.                                        3284 3380-3150 "
Carbonyl N-C=O                                            1688 1760-1650 "
     Halide          C-Cl             749                              800-600     "
    Ether         Ar-O-C           1238           1260-1200                  "
          1039           1100-1000                  "
N
N
O
NH
O
CH3
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Cl
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CH3
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Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (400 MHz)
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons
1.         0.88-0.97                       m                  4H                     HC–(CH2)2
2.        1.65-1.69                      m                  1H                      (H2C)2-CH
3.       2.30                      s                  3H                        CO–CH3
4.      3.79                      s                  3H                          -OCH3
5.       3.86-3.87                     d                  1H                         pyrz–Ha
6.       5.96-5.97                     d                  1H                         pyrz–Hb
7.        6.83-7.50                     m                  8H                            Ar-H
8.      9.98                      s                  1H                             N-H
Inference
NMR SPECTRAL STUDIES OF 1-N-ACETYL-(p-METHOXYPHENYL)AMIDO-3-CYCLOPROPYL-
5-(o-CHLOROPHENYL)-4,5-DIHYDRO-1H-PYRAZOLE.
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-N-A C E T Y L - 4 -
A R Y L A M I D O - 3 - C Y C L O P R O P Y L - 5 - ( o- CHLOROPHENYL)-4,5-
DIHYDRO-1H-PYRAZOLE.
(A) Synthesis of N-Aryl-3- cyclopropyl-3-oxo-propanamide.
           See  Chapter-1, Section  II (A), Page No.50.
(B) S y n t h e s i s  o f  3 - ( o - Ch l o r o p h e n y l ) - 2 - ( c y c l o p r o p y l c a r b o n y l ) - N -
(p-methoxyphenyl) acrylamide.
See  Chapter-2, Section  II (B), Page No.113.
(C) Synthesis of 1-N-Acetyl-4-(p-methoxyphenyl)amido-3-cyclopropyl-
5-(o-chlorophenyl)-4,5-dihydro-1H-pyrazole.
A mixture of  3-(o-Chlorophenyl)-2-(cyclopropylcarbonyl)-N-(p-methoxyphenyl)
acrylamide (3.55gm 0.01mol) in glacial acetic acid  (25 ml) and hydrazine hydrate (0.5gm,
0.01 mol) was heated on water bath at 70oC for 8 hrs.Cool the reaction mixture and
pour on the crushed ice. Filter the product and wash with water dry and recrystalize into
isopropyl alcohol. Yield 39%, m.p. 172oC  Anal.Calcd. for C22H22N3O3Cl  Calcd: C,
64.15; H, 5.38; N, 10.20 %, Found: C, 64.30; H,5.50; N, 10.45%.
TLC System : Ethyl acetate : Toluene (2 : 3).
Similarly, other 1-N-Acetyl-4-arylamido-3-cyclopropyl-5-(o-chlorophenyl)-4,5-
dihydro-1H-pyrazoles were prepared. The physical data are recorded in Table No.8.
(D) Biological evaluation of   1-N-Acetyl-4-arylamido-3-cyclopropyl-5-
(o-chlorophenyl)-4,5-dihydro-1H-pyrazoles.
Antimicrobial activity was carried out as described in Chapter-1, Section-1(B),
Page No.39. The zone of inhibition of the test solutions are recorded in Graphical Chart
No.8.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type
(VIII) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=o-nitrophenyl,
p-fluorophenyl substituents against B.coccus. The significant activity was observed in
compounds bearing R= m,p-dichlorophenyl, p-nitrophenyl, against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-
chlorophenyl, p-nitrophenyl against Aerogenes. In the case of P.aeruginosa all the
compounds were least active except R= m-methylphenyl, o-nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=m,p-dichlorophenyl, p-
fluorophenyl and p-methoxyphenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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 INTRODUCTION  :
1,4-Dihydropyridine is the significant subclass of pyridines, the best known
heterocyclic compounds which are associated with  number of pharmacological
activities.The credit for the discovery of 1,4-dihydropyridine goes to Hantzsch in 18821,2
published the synthesis in its simplest form involves heating an aldehyde, 1,3-diketone
and ammonia.
1,4-Dihydro pyridine contribute as an important class of compound in medicinal
chemistry,  leading to several new drugs currently  widely used especially as calcium
channel antagonist3
 
and other cardiovascular diseases also.
1,4-Dihydropyridines, whether symmetrical or unsymmetrical are expected for
their cardiovascular and other pharmacological properties. Sufficient literature is
available  regarding structure activity studies. 4-8
Earlier it was believed that, the dihydropyrimidine is useful only as calcium chennel
antagonist of new synthetic DHP molecules indicates that major use fo these calcium channel
activators may be broaden from ionotrophy to secretary stimulations also. Currently,
these drugs are used in angina, hypertension, hypetrophic cardiomyopathy,
cerebralvasospasm and other smooth muscle disorders.
The DHP nucleus is common to numerous bioactive compounds  which  include
various vasodilator,  antihypertensive, bronchodilator,  antiatherosclerotic,
hepatoprotective, antitumor, antimutagenic, geroprotective and antidiabetic agents.9-14
SYNTHETIC ASPECT :
In 1882,  1,4-dihydropyridine was introduced by Hantzsch1,2
 
 in a single step
preparation involving the condensation of an aldehyde, ammonia and acetoacetic
ester.1,4-Dihydropyridines are not only  intermediates for the synthesis of pyridines, but
are also an important class of N-heterocycles,15,16an example is the coenzyme NADH.
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Studies on the function of NADH led to increased interest in the synthesis of
dihydropyridines as model compounds. Aryl-substituted dihydropyridines have been
shown to be physiologically active as calcium antagonists. Some derivatives have found
application in the therapy of high blood pressure and angina pectoris.17For that reason
the synthesis of 1,4-dihydropyridines has been the subject of intensive research and
industrial use. The Hantzsch synthesis has thus become an important reaction.
Different synthetic methods for the synthesis of 1,4-dihydropyridine are as
follows.
(1). By the condensation of aromatic or aliphatic aldehydes with ethylacetoacetate
and aromatic or aliphatic amine in presence of pyridine.18,19
(2). By the condensation of aliphatic or aromatic aldehydes with 3-aminocrotonate
and 1,3 -diketone.20-26
(3). By the condensation of arylidine with 3-aminocrotonate.27
(4). By the condensation of aliphatic or aromatic aldehydes with various 1,3-
diketones in presence of ammonia or ammonium carbonate.28-30
(5). Shengkai Ko et al.31  have synthesized 1,4-dihydropyridine ( I )  by one pot
reaction, catalyse by iodine at room temperature.
O
O
+
CH3O
O
OC2H5
NH4OAc
I2
RT
N
H
OC2H5
CH3
OO Ar
O
Ar
                                                                                                         ( I )
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(6). When acetophenone reacted with 3-aminocrotonitrile gave sym.3,5-dicyano-2,
4,6-trimethyl-4-phenyl-1,4-dihydropyridine32(II) and aldehyde condensation with
3-aminocrotonitrile in suitable acidic medium like acetic acid or hydrochloric acid gave
sym.3,5-dicyano-2,6-dimethyl-4-substituted phenyl-1,4-dihydropyridine33,34.
RO
+
CH3
CNNH2 N
H
CH3CH3
CNNC R
2
R=H,CH3
(7).   Reaction of aryl grignard reagents with pyridine-3,4-dicarboxylic ester gave
the 4-aryl-2,6-disubstituted dihydropyridines( III ). Methyl Grignard is reported to give
mixtures of 2 and 4-substituted products.35
(8). Alexander Kornienko et al.36 have synthesize dihydropyridine derivatives by the
cyclocondensation of aldehyde and malononitrile and thioderivatives in the presence of
triethyl amine.
                                                                                                            ( II )
COOC2H5H5C2OOC
ArMgX N
H
COOC2H5H5C2OOC
                                                                                                       (III )
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O
R
CN
CN
R1 SH
N
H
NH2 S
CNNC
R
R1
Et3N
Ethanol
Reflux
+ +
REACTION MECHANISM OF 1,4-DIHYDRO PYRIDINES
The initial step of the Hantzsch synthesis is likely to be a Knoevenagel
condensation reaction of aldehyde (II) and β-ketoester (I) to give the α,β-unsaturated
ketoester (III). The enamine is formed by the condensation of the β-ketoester (I) and
ammonia. The ring synthesis then proceeds in subsequent steps by condensation of the
unsaturated ketoester (III) and enamine (IV) to yield a 1,4-dihydropyridine (V).37-43
                                                                                                                (IV)
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R1
H COOEt
O R1
COOEt
O
H
NH3 :
NH3 :
O
R H
R1
COOEt
O
OH
R
H
NH3:
R1
COOEt
O
OH
R -
R1
COOEt
O
R
enolate 
formation
aldol
condensation
R1
COOEt
O
NH3:
R1
COOEt
OH
NH2:
R1
COOEt
NH2 +
H
R1
COOEt
NH2
..
NH3 :
enamine
formation -H2O
R1
COOEt
NH2
..
R1
EtOOC
O
R
R1
EtOOC
O-
R
R1
COOEt
N
H
NH3 + H
R1
EtOOC
O
R
R1
COOEt
N
H
NH3 + H
R1
EtOOC
OH
R
R1
COOEt
N
H
+
HH
NH3:
NH3 :
: :
N
H
R
R1R1
COOEtEtOOC
conjugate 
addition
(I)
(II)
(III)
(I) (IV)
(IV)(III)
(V)
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 BIOLOGICALLY  DIVERSED  ACTIVITIES
Recently, synthesis and biological evaluation of 3,4-dihydro-6-methyl-5-N-
methylcarbamoyl-4-(Substituted phenyl)-2-(1H) pyrimidinones and pyrimidinethiones
(I) were studied.44 It was found to have antiinflammatory as well as analgesic activity to
a considerable extent. N-methylcarbamoyl moiety at 5-position was identified as
possible biological active site in these molecules.
NH
N
H
X
O
N
CH3
H
R
R1
R2
R3
CH3
                                                               Where   R = H ; OH ; Cl ; NO2
                                                                            R1 = R2 = H ; OH ; OCH3;
                                                                                           Cl ; NO2 ; OCH2O
                                                                            R3 = H and OCH3
                                                                            X  = O,S
                                           (I)
Subsequently, by the same research group45 synthesis and pharmacology of 2,6-
dimethyl-4-(substituted phenyl)-3,5-di [N-(methyl)/N-(dimethyl)] carbamoyl]-1,4-
dihydropyridine (II) was carrried out and again they established that in new substitued
1,4- dihydropyridines with certain structural modifications incorporation N-methyl and
N-diethyl carbamoyl moieties at the 3 and 5 positions gave not only calcium channel
blocking activity but again to some extent, antiinflammatory and analgesic profile was
also observed. The acute toxicity of these molecules was also investigated.
N
H
O
N
O
N
X
YY
X
CH3 CH3
                                                                                   3,4-di- OCH3 ; 3,4,5-tri-OCH3
                                                                                   2-NO2 ; 3-NO2 ; 2-Cl ; 4-Cl ;
                                                                                   2,4-di-Cl ;
                                                                             X = H ; C2H5
                                                                             Y = CH3 ; C2H5
                                           (II)
                                                     R         Where R = H ; CH3 ; OH ; OCH3 ; Br ;
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It was also interesting to note that the structures having 3,4,5 trimethoxyphenyl
moeity as well as 2,4-dichloro substituents appears to increase the calcium channel blocking
activity.
Very recently the patented compound (III) suggests that phenyl carbamoyl
moiety in dihydropyridine either at 3 and / or 5 position has proved to be good
cardiovascular compound for selective activity. 46
N
H
COOCH2CH2
O
NH
CH3 CH3
Cl
H
N
                     (III)
Similarly (IV) is found to be highly selective as platelet activating factor (PAF)
antagonist.47
N
H
O
NH
CH3
ClH
COOC2H5
N N
N
CH3
                                             UK - 74,505                (IV)
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THERAPEUTIC IMPORTANCE
Dihydropyridines are the largest and most studied class of drugs calcium channel
blockers.48 Many 1,4-dihydropyridine derivatives have been synthesized and devloped
as calcium channel antagonists which inhibit smooth and cardiac muscle contractions by
blocking the influx of Ca+2  through calcium channels and antihypertensive action.49-57
Besides this, vasodialator58,coronary vasodialator59, antitumor60, antiinflammatory61,
antimyocardiac  ischemic62,  antiarrhythmic activities63 and antiallergic64 are also  asso-
ciated with these molecules.
The DHP nucleus is common to numerous bioactive compounds  which include
various vasodilator,  antihypertensive, bronchodilator,  antiatherosclerotic,
hepatoprotective, antitumor, antimutagenic, geroprotective and antidiabetic agents65-70.
In  continuation of our earlier work on symmetric 1,4 dihydropyridines71-73 like
2,6- dimethyl-3,5-diacetyl-4-(substituted phenyl)-1,4-dihydropyrimidines, it was
observed that the symmetric dihydropyridines,if incorporated with carbamoyl
functionality, we may expect some different pharmacological profile for different screenings.
As suggested by Triggle74, removal of both ester functions at 3 and 5 positions may
completely avoid cardiovasular activity. This conclusion has also opened up new scope
for structural changes taking place at these positions.
 Among various cardiovascular 1,4-dihydropyridines, Nefidipine,Darodipine and
Flordipine are the compounds having symmetrical structure especially in their   ester
functionality  at 3 and 5 positions. Other drugs like Nimodipine ,Nicardipine,
Ni lvodip ine ,Fa lodip ine , I s rad ip ine ,Rheodip ine ,Amlodip ine ,Ni t rendip ine
Lacidipine,Bernidipine,Sangandipine, Benidipine, Furaldipine, Manidipine and Toludipine
(Table) are unsymmetric in differenting esteric linkage between 3- and 5- positions. The
methyl group at 2-position is replaced by carbon chain having amino or oxygen or sulfur
or combination functionality and their homologous alkane derivatives led to number of
future drug molecules75. The bioisoters of these compounds were also sudied to a
considerable extent76.
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DHPs have found commercial utility as calcium channel blockers, as exemplified
by therapeutic agents such as Nifedipine77 Nitrendipine78 and Nimodipine79. Second
generation calcium antagonists include DHP derivatives with improved bioavailability,
tissue selectivity, and/or stability,such as the antihypertensive/antianginal drugs like
Nimodipine80,Nicardipine81,82, Is radipine83,Ni t rendipine84 ,Flordipine85,
B e n i d i p i n e 8 6 , F e l o d i p i n e 8 7 , R i o d i p i n e 8 8 , N i l v o d i p i n e 8 9 , A m l o d i p i n e 9 0 ,
Darodip ine91,Ta ludip ine92,Lec id ip ine93 ,Sagandip ine 94 ,Lemi ld ip ine95 ,
Furnidipine96,Azelnidipine97.Barnidipine98,Efonidipine99,Iganidipine100,
Manidipine101.
Some of their compounds are characterized by longer bioactivity of greater tissue
selectivity.1,4-dihydropyridine derivatives are associated with diverse biological
activities viz.1,4- DHPs possess different pharmacological activities such as.
1. Myocardial infarction.102-104
2. Stable105,106 and unstable angina.107,108
3. Vasodilator.109
 4. Coronary vasodilator and cardiopathic.110
5. Antiarrhythmic.111
6. Antiulcer.112
7. Antiallergic.112
8. Antiinflammatory.113
9. Subarachnoid hemorrhage.114,115
10. Ischemic brain damage.116
11. Atherosclerosis.117
12. Heart failure.118
13. Calcium channel antagonism.119
14. Antitumor.120
15. Antimayocardiac ischemic.121
16. PAF antagonist.122
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The  symmetrical  dihydropyridines (V) having N-methyl or N-diethyl carbamoyl
function at 3 and 5 position in place of ester were also synthesised. These compounds
were tested for potent calcium channel blocking activity 127. Very recently, one of such
new DHP molecules NSC-372643 come out with its anti-HIV activity. Which has
opened up the synthetic as well as pharmacological importance of such molecules128.
N
H
CH3 CH3
OO
NH NH
RR
H
R
N
H
CH3 CH3
OO
NH NH
H
NO2
OH
OH
OH
OH
                              (V)                                                NSC-372643
It was found that ester functions  at 3 and 5 positions in1,4-dihydropyridine
nucleus can be replaced by dialkyl carbamoyl moiety (ethyl/methyl), Which can give
some other pharmacological activity than usual calcium channel blocking activity.
Stephen C. Textor et al.129 have reported dihydropyridine derivatives as calciam chennel
blocking agents.
Anil K. Chhillar et al.130 have synthesized dihydropyridine derivative (VI) and
reported their antimicrobial and antifungal activity.
17. Adenosine A3 receptor antagonist.
123
18. MDR reversal activity.124-125
19. Antitubercular agents.126
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N
H
COOC2H5
CH3CH3
H5C2OOC
OCH3
(VI)
Mosami Kawase  and co-workers131 have documented dihydropyridine
derivative (VII) as MDR reversal in tumor cells.
N
H
CH3CH3
COPhPhOC
Cl
(VII)
Shah  A.et al.125,132  have synthesized 4-phenyl-3,5-diacetyl-1,4-dihydropyridines
(AcDHPs) (VIII) and 4-phenyl-3,5-dibenzoyl-1,4-dihydropyridines (BzDHPs) (IX)
substituted at the phenyl ring and compared for their cytotoxic activity and multidrug
resistance (MDR) reversing activity in in vitro assay systems.
     154
N
H
OO
CH3 CH3
H
R
N
H
CH3
OO
CH3
CH3 CH3
H
Cl
(AcDHPs) (BzDHPs)
R= CF3,R= CF3, H, NO2, Cl etc.... H,
NO2, Cl etc....(((
Shah A.et al.133 synthesized  4-substituted phenyl-2,6-dimethyl-3,5-bis-(N-
substituted phenyl)- carbamoyl-1,4-dihydropyridine (X) and studied their 2D QSAR
as well as  antitubercular activity against M.tuberculosis H37Rv , among them some
derivatives show >90% inhibition comparable to rifampicin.
N
H
CH3 CH3
NH
OO
NH
R1
R1
R
R= 3-OC6H5,Cl NO2 Br .... R1= NO2, Cl, Br ....
(VIII)
(X)
(IX)
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Kilcigil and coworkers134 synthesized new type of symmetrical dicarbamoyl
1,4-dihydropyridine (XI) with some flavone derivatives at C4 position of DHP ring by
reacting 6-formylflavones with acetoacetanilide.Their aim was to investigate the calcium
antagonistic activity on this skeletal changes. Few  newly synthesized compounds showed
good calcium antagonistic activity  with  nifedipine as the reference compound.
N
H
CH3CH3
CO
NH
CO
NH
O
O
(XI)
Saponara and group135 have investigated the effects of AcDHPs and BzDHPs
on vascular functions in vitro by comparing their mechanical and electrophysiological
actions, as well as to quantify their MDR reversal properties.
Sonja136  and group have synthesized a new series of calcium channel agonists
(XII) structurally related to Bay K8644, the racemic mixtures were studied for their
action on L-type Ca2+ channels expressed in cultured rat insulinoma  cells. All the products
proved to be potent calcium channel agonists.
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(XII)
N
H
O
O
CH3 NO2
CH3CH3
O
O
N N
R
R = CN,CONH2 , CH3 etc...
N
H
O
O
CH3 NO2
CH3CH3
CF3
Bay K8644
Carlos Velazquez and Edward E. Knaus137  have reported pyridine derivatives
(XIII) as potential treatment of congestive heart failure.
R
N
H
CH3CH3
O
O
O2N N
CH3
N
N
O O CH3
O
O
(XIII)
1,4-Dihydropyridine containing 3-methoxy-flavone moiety (XIV)have synthesized
by Roberta Budriesi et al.138 and reported as calcium channel modulators.
O
O
OCH3
N
H
COOC2H5
CH3CH3
H5C2OOC
(XIV)
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In light of wide varieties of biological activities exhibited by dihydropyridines, it
appeared of interest to synthesize dihydropyridine derivatives in order to achieving com-
pounds having better therapeutic activity described as under.
SECTION-I  : SYNTHESIS AND THERAPEUTIC EVALUATION
OF 3,5-DI-ARYLAMIDO-2,6-DICYCLOPROPYL
4-(p-METHOXYPHENYL)-1,4-DIHYDROPYRIDINES.
SECTION-II  : SYNTHESIS AND THERAPEUTIC EVALUATION
O F M E T H Y L - 5 - A RY L A M I D O - 4 - ( o - C H L O R O -
P H E N Y L ) - 6 - C Y C L O P R O P Y L - 2 - M E T H Y L - 1 , 4 -
D I H Y D R O P Y R I D I N E - 3 - C A R B O X Y L AT E S .
     158
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3,5-DI-ARYLAMIDO-
2,6-DICYCLOPROPYL4-(p-METHOXYPHENYL)-1,4-DIHYDROPYRIDINES.
1,4-Dihydropyridine derivatives have drown considerable attention in view of their
potential pharmacological properties such as antimicrobial, anticonvulsant, anticancer,
etc. The synthesis of 1,4-dihydropyridines derivatives of type-(IX) has been under-
taken. The synthesis was carried out by the condensation of 2-mole of  N-Aryl-3-
cyclopropyl-3-oxo-propanamide and p-methoxy benzaldehyde and methanolic ammo-
nia  shown as under.
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further  supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
O
CH3
N
H
O
NH
R
O
NH
R
          Type (IX)                R=Aryl
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REACTION SCHEME
O
OMe
O
+
O
O
NHR+
Toluene
R= Aryl
N
H
O
NH
R
O
CH3
O
NH
R
O
O
CH3
R
NH2
+O
O
NHR
Methanolic 
Ammonia
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I R  S P E C T R A L  S T U D I E S  O F  3 , 5 - D I - A M I D O P H E N Y L - 2 , 6 - D I C Y C L O P R O P Y L
4-(p-METHOXYPHENYL)-1,4-DIHYDROPYRIDINE.
 Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2920.5 2975-2950 139
–CH3 C – H str. (sym.) 2833.5 2880-2860 "
C – H def. (asym.) 1436.9 1470-1435 "
 –C–CH2 C – H def.                                    1383.8 1385-1365 "
Aromatic =C – H str. 3083.9 3090-3030 "
C = C str 1629.7 1612-1550 "
1585.4 1585-1573 "
C – H i.p. (def) 1243.0 1269-1247 "
1122.8 1181-1171 "
C – H o.o.p. (def) 795.6 832-802 "
Pyridine C = C str. 1518.8 1580-1520 140-141
C – N 1220.9 1300-1200 "
N – H str. 3416.3 3440-3300 "
Carboxamide C =O 1683.7 1680-1630 "
N – H str. 3243.0 3380-3150 "
N
H
NH
OO
NH
O
CH3
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N M R  S P E C T R A L  S T U D I E S  O F  3 , 5 - D I - A M I D O P H E N Y L - 2 , 6 - D I C Y C L O P R O P Y L
4-(p-METHOXYPHENYL)-1,4-DIHYDROPYRIDINE.
Internal Standard : TMS; Solvent : DMSO  : Instrument : BRUKER Spectrometer (300 MHz)
Signal
No.
Multiplicity
Signal Position
(δ ppm)
Relative No.
of Protons
1.         0.48-0.81                 m                8H                      [HC–(CH2)2]2
2.         2.20-2.37                m                2H                      [(H2C)2–CH]2
3.       3.35                s                3H                            -OCH
3
4.     4.43                s                1H                            pyr–H
5.     6.73-7.53                m              14H                              Ar-H
6.     10.0                s               1H                             N–H
7.      10.27                s               2H                           [N–H]2
Inference
O
CH3
N
H
NH
OO
NH
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EXPERIMENTAL
S Y N T H E S I S  A N D  T H E R A P E U T I C  E VA L U AT I O N  O F  3 , 5 - D I -
A R Y L A M I D O - 2,6-DICYCLOPROPYL-4-(p-METHOXYPHENYL)-1,4-
DIHYDROPYRIDINES.
(A) Synthesis of N-Aryl-3-cyclopropyl-3-oxo-propanamide .
           See Chapter-1, Section  II (A), Page No.50.
(B) Synthesis of 3,5-Di-amidophenyl-2,6-dicyclopropyl-4-(p-methoxyphenyl)
-1,4-dihydropyridine.
A mixture of  3-Cyclopropyl-N-phenyl-3-oxopropanamide (4.66gm 0.02mol)
and p-methoxy benzaldehyde(1.40gm, 0.01mol) in methanolic ammonia was refluxed
on water bath for 12 hrs. Cooled the reaction mixture at room temprature and stand by
for a day. The resulting solid mass was filtered and washed with methanol. Recrystalized
the product in  DMF and methanol. Yield 45%. m.p.190oC. Anal.Calcd. for C32H31N3O3
Calcd: C,76.02; H, 6.18; N, 8.31 %, Found: C, 76.25; H,6.30; N,8.46%.
Similarly, other 3,5 -Di-arylamido-2,6-dicyclopropyl-4-(p-methoxyphenyl)-1 ,4-
dihydropyridines were prepared. The physical data are recorded in Table No.9.
(D) Bio log ica l  eva luat ion  o f  3 ,5 -Di -ary lamido-2 ,6 -d icyc lopropyl -4 -
(p -methoxyphenyl)-1 ,4 - dihydropyridines.
Antimicrobial activity was carried out as described in Chapter-1, Section-1(B),
Page No.39.The zone of inhibition of the test solutions are recorded in Graphical Chart
No. 9.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (IX)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=m-
nitrophenyl, p-fluorophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= m-methylphenyl, p-fluorophenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-chloro
phenyl,p-fluorophenyl against Aerogenes. In the case of P.aeruginosa  all the compounds
were least active except R= m,p-dichlorophenyl, p-nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R= m-nitrophenyl and p-
nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-II
SYNTHESIS AND THERAPEUTIC EVALUATION OF METHYL -5-
ARYLAMIDO-4-(o-CHLOROPHENYL)-6-CYCLOPROPYL-2-METHYL -1,4-
DIHYDROPYRIDINE-3-CARBOXYLATES.
It is well known that 1,4-dihydropyridines and related compounds exhibit a wide
range of biological activities. Looking to the interesting therapeutic activity,  we prepared
compounds of type (X) which have been synthesized by the condensation of  N-Aryl-3-
(o-chlorophenyl) -2-(cyclopropylcarbonyl)-acrylamide and methyl-3-aminocrotonate.
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
N
H
CH3
OO
NH
R
O
CH3
Cl
 Type (X)           R=Aryl
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REACTION SCHEME
O
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O
+
O
O
NHR +
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ToluenePiperidine
+
CH3NH2
O
O
CH3
R
NH2
O
Cl
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O
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R
Cl
methanol
N
H
O
NH
CH3
O
O
CH3
Cl
R
R = Aryl
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IR SPECTRAL STUDIES OF METHYL -5-(p-NITROPHENYL)AMIDO-4-(o-CHLOROPHENYL)
-6-CYCLOPROPYL-2-METHYL-1,4-DIHYDROPYRIDINE-3-CARBOXYLATE.
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2965 2975-2950 139
–CH3 C – H str. (sym.) 2847 2880-2860 "
C – H def. (asym.)                          1422 1470-1435 "
 –C–CH2 C – H def.                                       1367 1385-1365 "
 Aromatic C – H str.                                        3022 3090-3030 "
C = C str                                         1596 1612-1550 "
Pyridine C = C str. 1596 1580-1520 140-141
C – N 1300 1300-1200 "
N – H str. 3379 3440-3400 "
Carboxamide C =O 1653 1680-1630 "
N – H str. 3296 3380-3150 "
 Ether                     Ar-O-C           1237             1260-1200 "
Ester C = O                        1711                    1730-1700                  "
  Nitro         N=O                                     1515                  1570-1500     "
 NO2                                               1367                   1370-1300                   "
  Halide                      C-Cl                                               734                       800-600                    "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
N
H
O
NH
CH3
COOCH3
H
ClN
+
O-
O
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NMR SPECTRAL STUDIESOF METHYL-5-(p-NITROPHENYL)AMIDO-4-(o-CHLOROPHENYL)-
6-CYCLOPROPYL-2-METHYL-1,4-DIHYDROPYRIDINE-3-CARBOXYLATE.
1.       0.65-0.79                m             4H                         HC–(CH
2
)2
2.       2.06-2.08               m             1H                       (H
2
C)
2
-CH
3.      2.38               s             3H                           Ar-CH
3
4.     3.05               s             3H                       CO-OCH
3
5.    5.39              s             1H                           Pyr–CH
6.     7.05-8.11             m             8H                          Ar–H
7.                 (Overlapped)             1H                             N-H
8.   9.67              s             1H                              N-H
Signal
No.
Multiplicity
Signal Position
(δ ppm)
Relative No.
of Protons Inference
Internal Standard : TMS; Solvent : DMSO  : Instrument : BRUKER Spectrometer (400 MHz)
N
H
O
NH
CH3
COOCH3
ClN
+
O-
O
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SYNTHESIS AND THERAPEUTIC EVALUATION OF METHYL -5-
ARYLAMIDO-4-(o-CHLOROPHENYL)-6-CYCLOPROPYL-2-METHYL-
1,4-DIHYDROPYRIDINE-3-CARBOXYLATES.
(A) Synthesis of N-Aryl-3-cyclopropyl-3-oxo-propanamide.
See  Chapter-1, Section  II (A), Page No.50.
(B) Synthesis of N-Aryl-3-(o-chloro phenyl)-2-(cyclopropylcarbonyl)-
acrylamide.
See Chapter-2, Section  II (B), Page No.113.
(C) Synthesis of Methyl-5-(p-nitrophenyl)amido-4-(o-chlorophenyl)-6-
cyclopropyl-2-methyl-1,4-dihydropyridine-3-carboxylate.
A mixture of  3-Cyclopropyl-N-(p-nitrophenyl)-3-oxopropanamide(3.70gm
0.01mol) and methyl-3-amino crotonate (1.15gm, 0.01mol) in methanol was refluxed in
water bath for 18hrs. Cooled down reaction mixture at room temperature and stand by
24 hrs. The resulting solid mass was filtered and washed with methanol. Recrystalized
the product in methanol.Yield 45 %, m.p. 200oC. Anal.Calcd. for C24H22N3O5Cl Calcd:
C,61.61; H, 4.74; N,8.98 %, Found:  C,61.78; H,4.88; N,9.13 %.
Similarly, other Methyl-5-arylamido-4-(o-chlorophenyl)-6-cyclopropyl-2-
methyl-1,4-dihydropyridine-3-carboxylates were prepared. The physical data are
recorded in Table No. 10.
(C) Biological evaluation of Methyl-5-arylamido-4-(o-chlorophenyl)-6-
cyclopropyl-2-methyl-1,4-dihydropyridine-3-carboxylates.
Antimicrobial testing were carried out as described in Chapter-1, Section-
1(B), Page No.39.The zones of inhibition of test solutions are recorded in Graphical
Chart No. 10.
EXPERIMENTAL
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (X)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
chlorophenyl, p-methylphenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= m-chlorophenyl, p-fluorophenyl, p-methylphenyl
against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-chloro
phenyl,p-nitrophenyl against Aerogenes. In the case of P.aeruginosa all the compounds
were least active except R= p-methoxyphenyl, p-nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=m,p-dichlorophenyl,
m-methylphenyl and p-nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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INTRODUCTION
Pyridine is also called azabenzene and azine, is a heterocyclic aromatic tertiary
amine characterized by six-membered ring structure composed of five carbon atoms
and a nitrogen atom which replaces one carbon-hydrogen unit in the benzene ring
(C6H5N).Most of the derivatives are prepared by manipulation of pyridine and its simple
homologues in a manner similar to chemistry of the benzenoid chemistry. However, the
simple pyridine compounds are prepared by the cyclization of aliphatic raw materials.
Pyridine compounds are found in nature, for example nicotine from tobacco, ricinine
from castor bean, alkaloids such as coniine, piperine and nicotine.Some pyridine system
is active in the metabolism in the body. pyridine can be parent componant of targeted
compounds such as insecticides, herbicides, medicines, vitamines, food flavoring,
explosive and disinfectants.
Among a wide range of pyridines, 3-cyanopyridines (I) acquired a special
attention due to their wide range of therapeutic activities.In our continuation of work in
the chemistry of pyridine nucleus, we have undertaken the synthesis of some 3-
cyanopyridine derivatives.
SYNTHETIC ASPECTS
Preparation of 3-cyanopyridines have been cited in literature1-6 with different
methods.
1. Dao-Lin & Kimiaki.7 have prepared 2-methoxy-3-cyanopyridine derivatives by the
condensation of chalcones with malononitrile in sodium methoxide.
N
CN
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N R'
R
H3CO
N
NaOMe
N
N
+
R
O
R'
2. 2-Trihalomethyl 5-cyanopyridine have been synthesised by Jason WB Cooke8
OEt CF2X
O
+
CN
NMe2
Toluene
NH4oAC
DMF N CF2X
NC
X=Cl, F, I
3. Sakuri and Midorikaw9,10 have reported that malononitrile reacts with α,β-
unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines.
4. Feng Shi and co-workers11 have prepared 2-amino-3-cyanopyridine derivative
by the reaction of aromatic aldehyde, ketone, malononitrile and ammonium
acetate under microwave irradiation without solvent.
MECHANISM
The reaction proceeds through conjugate addition of active methylene
compounds to the α,β-unsaturated system as shown below.
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THERAPEUTIC IMPORTANCE
Much research has been carried out with an aim to finding therapeutic values of
pyridine skeleton since their discovery. The pyridine derivatives are reported to exhibit
a wide variety of biological activities.
1. Antifungal12
2. Antiepileptic13
3. Antibacterial14
4. Anticonvulsant15
5. Analgesic16
6. Insecticidal17
7. Antisoriasis18
8. Antihypertensive19
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Guru S. et al.20 have synthesized various cyanopyridyl derivatives (II) and
documented their multiple biological activities.The oxide activator bleaching activity of
O
N
NH2
R
N
(II)
 Rees M.21 and Oshida M.22 prepared cyanopyridine derivatives which inhibit
cerebral edema and delayed neuron death hence,they are useful as cerebral edema
inhibitors or cerebrovascular disorder remedies. The insecticidal activity of cyanopyridines
have been screened by Sasaki Y. et al.23Aivars Kruaze et. al.24 have synthesised 3-
cyanopyridine derivatives & shown their neurotropic activity.
This effect was significantly higher that induced by Piracetam at 50 mg/kg. Manna F.
et al.25 have prepared 3-cyanopyridine derivatives as antiinflammatory, analgesic and
antipyretic agent. Some new 3-cyanopyridine derivatives synthesized by Hammama A.
and coworkers26  showed anticancer and anti HIV-I activity. Abdallah N. et al.27 have
synthesized and reported analgesic and antiinflammatory activity. Roman S. V. et al.28
have investigated 2-amino-3-cyanopyridine derivatives and reported their biological
activity.
Abu and co-workers29 have described novel fused cyanopyridines for the
treatment of fungal infection. El-Tawell and co-workers30 have described cyanopyridine
derivatives (III) and showed their significant biological activity. Pyachenko U.D. and
co-workers31 have shown some cyanopyridines (IV) which are useful in treatment of
retroviral disease. Hironori et al.32 have prepared cyanopyridines and screened for their
large conductance calcium activated potassium channel opener activity.
cyanopyridine has been proved.
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(IV)
N
N
N
NH2
Se
N
O
NH2NC
(III)
Edwin B. Villhauer and co-worker33 have reported the first use of solid-phase
synthesis in the discovery of a new DPP-IV inhibitor class and a solution-phase synthesis
that is practical up to the multikilogram scale. One compound, NVP-DPP728 (V), is
profiled as a potent, selective and shortacting DPP-IV inhibitor that has excellent oral
bioavailability and potent antihyperglycemic activity.
N NH
NH
O
N
CN
NC
(V)
Wu Wenxue et al.34 have synthesized cyanopyridines as histamine H3
antagonists.Moustafa M. A. et al.35 have prepared cyanopyridines as antibacterial agents.
Rosentreter Ulrich et al.36 have synthesized a new cyanopyridine as receptor agonists in
the treatment of cancer disease , inflammation, neurodegenerative disease(VI).Fatma
Goda & co-workers37 have synthesised 2-alkoxy pyridines (VII) and studied their
antimicrobial activity.
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N
CN
CNR2CH2S
NH2
O(CH2)n OR1
(VI)
N
N
O
Ar
Ar
CH3(VII)
Ketan Hirpara & co-workers38 have discovered cyanopyridines as an
antitubercular agents (VIII). Eduardo H, S. Sousa et al39 have synthesized cyanopyridine
derivetives as an antituberculosis.
N
N
S
N
NH2
N
R
(VIII)
Recently,Gary T. Wang and co-workers40 have synthesized o-trifluoromethyl
biphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase(IX).
Fokas H. and co-workers41 have synthesized cyanopyridine derivatives and reported
their antimicrobial activity. These compounds were tested in vitro for their activity towards
25 strains of anaerobic and 25 strains of aerobic bacteria. They showed good activity
towards the anaerobic bacteria.
N
O
N
N
NC
N
R1
R2
F3C
CN
CH3
(IX)
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El-Nabawia et al.42 have prepared new 2-amino-3-cyanopyridine derivatives
(X) and studied their antimicrobial activity.
N
N CH3
C CH3
O
R
C
NH2
N
(X)
Abdallah N. et al.43 have synthesized cyanopyridine derivatives which showes
analgesic and antiinflammatory activity. Adriano Atonso et al.44 have found that
cyanopyridines are Fernesyl protein tranferase inhibitors.  Aivars Kruaze et al.45 have
synthesized 3-cyanopyridine derivatives & shown their neurotropic activity. Abu and
co-workers46 have described novel fused cyanopyridines (XI) for the treatment of
systemic fungal infection.
(XI)
N S
N
NH2
N
NH2
N
CH3
Abdel-Galil E. Amr and Mohamed M. Abdulla47 have synthesized heterocyclic
pyridine derivatives (XII) fused with steroidal structure. Initially the actual toxicity of
the compounds was assayed via the determination of their LD50. Heterocyclic pyridine
fused with steroid structure are active as antiinflammatory agents.
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In light of wide varieties of biological activities exhibited by cyanopyridine, it
appeared of interest to synthesize cyanopyridine derivatives in order to achieving
compounds having better therapeutic activity described as under
SECTION-I: SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-
A RY L A M I D O 4 - ( o - C H L O R O P H E N Y L ) - 3 - C YA N O - 6 -
CYCLOPROPYL-2-METHOXY  PYRIDINES.
SECTION-II : SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-
ARYLAMIDO-4- (o -CHLOROPHENYL)-3 -CYANO-6-
CYCLOPROPYL-2-ETHOXY PYRIDINES.
N
O
CH3
Ar
N
CH3
CH3
CH3
(XII)
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF  5-ARYLAMIDO-4-(o-
CHLOROPHENYL)-3-CYANO-6-CYCLOPROPYL-2-METHOXY  PYRIDINES.
The pyridine nucleus is found in a large number of commonly used drugs which
have diverse pharmacological activities. To achieving better drug potency cyanopyridine
derivatives of type (XI) have been prepared by the condensation of N-Aryl-3-(o-chloro
phenyl) -2-(cyclopropylcarbonyl)-acrylamide and malononitrile in sodium methoxide
solution.
 Type (XI)                           R=Aryl
N
O
NH
R
O
CH3
N
Cl
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analysis, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further  supported by Mass spectrometry.Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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O
+
O
O
NHR +
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O
O
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ToluenePiperidine
+
R= Aryl
CN
N
NaOCH3
N O
O
NH
R
CH3
Cl
CN
O
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R
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REACTION SCHEME
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IR SPECTRAL STUDIES OF 5-PHENYLAMIDO-4-(o-CHLOROPHENYL)-3-CYANO-6-
CYCLOPROPYL-2-METHOXY  PYRIDINE.
Alkane C – H str.(asym.) 2915.5 2975-2950 48
–CH3 C – H str. (sym.) 2832.3 2880-2860 "
C – H def. (asym.)                       1450.3 1470-1435 "
 –C–CH2 C – H def.                                    1359.7 1385-1365 "
 Aromatic C – H str.                                     3061.6 3090-3030 "
C = C str                                      1584.4 1612-1550 "
1510.2 1580-1450 "
Pyridine C = C str. 1606.6 1680-1580 49-50
C=N str. 1557.4 1580-1550 "
Carboxamide C =O 1668.8 1680-1630 "
N– H str. 3346.3 3380-3150 "
Nitrile C=N str. 2215.1 2240-2220 "
Chloride C-Cl str 799.4 800-600 "
Ether C-O-C 1209.3 1200-1260 "
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
N
O
NH
O
CH3
N
Cl
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Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (300 MHz)
Signal
No.
Multiplicity
Signal Position
(δ ppm)
Relative No.
of Protons Inference
1. 1.10-1.24                     m                4H                         HC–(CH2)2
2. 2.49                     m                1H                         (H2C)2–CH
3. 3.9-4.0                    s                3H                              -OCH3
4.   6.95-7.87                     m                9H Ar-H
                   (Overlapped)
5. 8.23                    s                1H N–H
NMR SPECTRAL STUDIES OF 5-PHENYLAMIDO-4-(o-CHLOROPHENYL)-3-CYANO-6-
CYCLOPROPYL-2-METHOXY  PYRIDINE.
N
O
NH
O
CH3
N
Cl
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYLAMIDO-4-(o-
CHLOROPHENYL)-3-CYANO-6-CYCLOPROPYL-2-METHOXY  PYRIDINES.
A) Synthesis of N-Aryl-3- cyclopropyl-3-oxo-propanamide.
           See Chapter-1, Section II (B), Page No.50.
(B) Synthesis  of  N-Aryl-3-(o-chlorophenyl)-2-(cyclopropylcarbonyl)-
acrylamide.
See Chapter-2, Section no II (B), Page No.113.
(C) Synthesis of 5-Phenylamido-4-(o-chlorophenyl)-3-cyano-6-cyclopropyl
-2-methoxy  pyridine.
To a solution of  N-Phenyl-(o-chlorophenyl)-2-(cyclopropylcarbonyl)-acrylamide
(2.34gm,0.01mol) and malononitrile (0.66gm,0.01 mol)  in methanol add freshly prepared
sodium methoxide solution to the reaction mixture with stirring, slowly heat the reaction
mixture at 50oC for 8hrs. cooled the reaction mixture and poured into crushed ice. Filtered
the product and washed with water, dry and recrystalized from ethyl acetate. Yield 45%
m.p. 95oC  Anal.Calcd. for C23H20N3O2Cl Calcd: C,68.08; H,4.97; N,10.40%, Found:
C, 68.50; H,5.10; N,10.64 %.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 5-Arylamido-4-(o-chlorophenyl)-3-cyano-6-cyclopropyl-2-
methoxy  pyridines were prepared. The physical data are recorded in Table No. 11.
(D) Biological evaluation of 5-Arylamido-4-(o-chlorophenyl)-3-cyano-6-
cyclopropyl-2-methoxy  pyridines.
Antimicrobial activity was carried out as described in Chapter-1, Section-1(B),
Page No.39. The zone of inhibition of the test solutions are recorded in Graphical Chart
No.11.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type (XI)
were found to be mild to moderately active against Gram positive and Gram negative
bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
methoxyphenyl, p-fluorophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= o-nitrophenyl, p-fluorophenyl,  against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-chloro
phenyl,p-fluorophenyl against Aerogenes. In the case of P.aeruginosa  all the compounds
were least active except R= m,p-dichlorophenyl,o-nitrophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=m-chlorophenyl, p-
fluorophenyl and m-nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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            SECTION-II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYLAMIDO-
4 - ( o -CHLOROPHENYL)-3 -CYANO-6-CYCLOPROPYL-2-ETHOXY
PYRIDINES.
It is well known that cyanopyridine and related compounds exhibit a wide range
of biological activities. Looking to the interesting therapeutic activities,  we prepared
compounds of type (XII) which have been synthesized by the condensation of N-
Aryl-3-(o-chloro phenyl)-2-(cyclopropylcarbonyl)-acrylamide and malononitrile in
sodium ethoxide solution.
    Type (XII)                        R=Aryl
N
O
NH
R
O
CN
Cl
CH3
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
O
OMe
O
+
O
O
NHR +
Toluene
O
O
NH
R
Cl
ToluenePiperidine
+
R= Aryl
CN
N
N O
O
NH
R
Cl
CN
CH3
O
Cl
R
NH2
NaOCH2CH3
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IR SPECTRAL STUDIES OF 5-PHENYLAMIDO-4-(o-CHLOROPHENYL)-3-CYANO-6-
CYCLOPROPYL-2-ETHOXY  PYRIDINE.
Alkane C – H str.(asym.) 2923.9 2975-2950 48
–CH3 C – H str. (sym.) 2837.1 2880-2860 "
C – H def. (asym.)                       1450.4 1470-1435 "
 –C–CH2 C – H def.                                    1363.6 1385-1365 "
 Aromatic C – H str.                                     3041.5 3090-3030 "
C = C str                                      1598.9 1612-1550 "
1502.4 1580-1450 "
Pyridine C = C str. 1608.5 1680-1580 49-50
C=N str. 1555.4 1580-1550 "
Carboxamide C =O 1660.6 1680-1630 "
N-H str. 3313.8 3380-3150 "
Nitrile C=N str. 2218.0 2240-2220 "
Chloride C-Cl str 754.5 800-600 "
Ether C-O-C 1220.9 1200-1260 "
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
    1029.9        1100-1000   "
N
O
NH
O
N
Cl
CH3
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
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NMR SPECTRAL STUDIES OF 5-PHENYLAMIDO-4-(o-CHLOROPHENYL)-3-CYANO-6-
CYCLOPROPYL-2-ETHOXY  PYRIDINE.
Internal Standard : TMS; Solvent : DMSO   : Instrument : BRUKER Spectrometer (300 MHz)
Signal
No. Multiplicity
Signal Position
(δ ppm)
Relative No.
of Protons Inference
1.        1.00-1.21                  m               4H                       HC–(CH2)2
2.        1.40-1.41                  t               3H                        CH2-CH3
3.         2.05-2.21                   m               1H                     (H2C)2–CH
4.         3.92-4.01                  q               2H                       CH3-CH2
5.        7.00-7.88                  m               9H                           Ar-H
                   (Overlapped)
6.    8.01                 s               1H                           N–H
N
O
NH
O
N
Cl
CH3
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 5-ARYLAMIDO-4-(o-
CHLOROPHENYL)-3-CYANO-6-CYCLOPROPYL- 2-ETHOXY PYRIDINES.
A) Synthesis of N-Aryl-3- cyclopropyl-3-oxo-propanamide.
           See Chapter-1, Section II (B), Page No.50.
(B) Synthesis of N-Aryl-3-(o-chlorophenyl)-2-(cyclopropylcarbonyl)-
acrylamide.
See Chapter-2, Section II (B), Page No.113.
(C) Synthesis of 5-Phenylamido-4-(o-chlorophenyl)-3-cyano-6-cyclopropyl
-2-ethoxy  pyridine.
To a solution of  N-Phenyl-(o-chlorophenyl)-2-(cyclopropylcarbonyl)-acrylamide
(2.34gm 0.01mol) and malononitrile (0.66gm, 0.01 mol)  in ethanol  add freshly prepared
sodium ethoxide solution to the reaction mixture under stirring, slowly heat the reaction
mixture at 50oC for 8hrs. cooled the reaction mixture and poured on to the crushed ice.
Filtered the product and washed with water, dried and recrystalized from ethyl acetate.
Yield 45 %  m.p.120oC  Anal.Calcd. for C24H22N3O2Cl2Calcd: C,68.85; H,5.28;
N,10.06%, Found: C, 68.99; H,5.50; N, 10.30%.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 5-Arylamido-4-(o-chlorophenyl)-3-cyano-6-cyclopropyl-2-
ethoxy  pyridines were prepared. The physical data are recorded in Table No. 12.
(D) Biological evaluation of  5-Arylamido-4-(o-chlorophenyl)-3-cyano-6-
cyclopropyl-2-ethoxy  pyridines.
Antimicrobial activity was carried out as described in Chapter-1, Section-1(B),
Page No.39. The zone of inhibition of the test solutions are recorded in Graphical Chart
No. 12.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type
(XII) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=m-
methylphenyl, m-nitrophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= p-chlorophenyl, m-nitrophenyl  against S.aureus.
The maximum activity was displayed by the compounds bearing R= m,p-dichloro
phenyl, p-fluorophenyl against Aerogenes. In the case of P.aeruginosa all the
compounds were least active except R= p-methylphenyl, p-fluorophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=o-nitrophenyl, p-
nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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The medicinal use of quinoline derivatives dates back more than 350 years. The
first compound was a natural one known as Quinine1 which is still important drug for
treating Chloroquine and multidrug resistant falciparum malaria. It is the chief alkaloid
of the south American Cinchona tree’s bark. In the year 1633, an Augustiniam monk
named Calancha; of Lima peru; first wrote that a powder of Cinchona givan as a bever-
age cure the fevers. It was employed for medicine as a powder, extract or infusion for
almost two centuries.
 The search  for  synthetic antimalarial other than Quinine derivatives initiated in
Germany early in the twentieth century. It was based on the observation of Guttman and
Ehrlich2 made in 1891 that the dye methylene blue and some chemotherapeutic effect on
malaria in patients. In 1920s the first synthetic antimalarial agent, Pamaquine was
synthesized by Schulemann et al.3 Which is 8-amino quinoline derivative. After that many
8-amino quinoline derivatives such as , Pentaquine4 and Primaquine5 were synthesized.
The quinoline nucleus found in several natural compounds (cincona alkaloids)
and pharmacologically active substances displaying a broad range of biological
activity.6-8 In addition to the medicinal applications, quinolines have been employed in
the study of bioorganic and bioorganometallic processes.9-11
INTRODUCTION
SYNTHETIC ASPECT
The literature survey reveals that several named organic reactions, publications
and patents described the synthesis of quinolines as under.
1. Skraup quinoline synthesis.12
Quinoline from aniline, glycerol, sulphuric acid and oxidizing agent.
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NH2
OH
OH
OH
N
Con H2SO4
Ph NO2
+
2. Friedlander synthesis13
Quinoline synthesis from the condensation of o-aminobenzaldehyde with
α-methylene carbonyl compound.
NH2
CHO
N R1
O
O
Et
+
R1
O
O
O
Et
3. Combes quinoline synthesis.14
Acid catalysed condensation of aniline and β-diketones to assemble quinolines
NH2 N
R2
R1
Con H2SO4+
R1
O
R2
O
4. Conrad-Limpach reaction15
Thermal or acid-catalysed condensation of aniline and β-ketoester leads to
quinolin-4-one.
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NH2 N
H
O
R1
+
R1
O
O
O
Et
Ph2O
260 oC
5. Niementowski Quinoline synthesis.16
Synthesis of 4-hydroxyquinoline by the action of carbonyl compound on anthranilic
acid is referred as a Nimentowski quinoline synthesis.
NH2
COOH
+
N
OH
R1
R2
R2
O
R1
6. Knorr Quinoline synthesis.17
The construction of 2-hydroxyquinoline or 2-quinolone by the treatment of β-
keto ester with aryl amine above 100oC is regarded as Knorr quinoline synthesis. The
intermediate anilide undergoes cyclodehydration with concentrated sulphuric acid.
NH2
+
N
CH3
OH
O
OEt
O
CH3
NH O
O
CH3
Con H2SO4
N
H
CH3
O
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8. Gould-Jacobs reaction.19
Synthesis of 4-hydroxyquinoline by the action of alkoxymethylenemalonic ester
or acylmalonic ester on arylamine is known as Gould-Jacob reaction.
NH2
+
N
OH
EtO H
O
OEt
O
EtO
7. Doebner reaction.18
The preparation of sustituted cinchonic acid by the condensation of an arylamine,
aliphatic or aromatic aldehyde and pyruvic acid is known as the Doebner reaction.
NH2
+
CH3
COOH
O
CH3
O
Ph
N Ph
9. Pfitzinger quinoline synthesis20.
Quinoline-4-carboxylic acid from the condensation of  isatic acid and α-methylene
carbonyl compound using base.
N
H
O
O
N R1
R2
COOH
R1
O
R2+
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10. Doebner-von Miller synthesis.21
The α,β unsaturated aldehyde like crotonaldehyde reacts with aromatic amine to
yield quinoline derivatives.
NH2
+
N CH3
H
O
CH3
Reaction mechanism of the Knorr Quinoline synthesis.
The mechanism involves two step, in first step the amino group reacts with β-
keto ester to furnish the anilide which on  cyclisation  in the presence of acid by the loss
of water molecule to afford quinoline derivative.
REACTION MECHANISM
NH2 H5C2O O
CH3
O
NH
O-
OC2H5
CH3
O
..
H+
NH O
CH3
OH +
..N+ O
CH3OH
H
H
H+
N+ O
CH3OH2 +
H
H
H
N O
CH3
H
-EtOH
-H2O
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Reaction mechanism of the Friedlander synthesis.
R
O
R1
H
OH -
NH2
O
H
R
O
R1
Aldol
condensation
OH R
H
NH2
COR1
OH -
NH2
R
R1O..
N
H
OH
R1
R
OH -
N R1
R
THERAPEUTIC IMPORTANCE
The study of quinolone derivatives were undertaken to determine the effect of
structure modification of quinoline compounds on the biological activities. Holmes R.
R.22 had reported that the metabolic products of certain antimalarials have been shown
to quinoline, quinones and carbostyrils. In 1962, Lesher et al. prepared nalidixic acid23
(1,8-napthyridine derivative) by adopting chemistry developed previously for the
synthesis of antimalarial drugs. Its utility was largely limited to the treatment of Gram-
negative urinarytrack infections. This research led the evaluation and development of
new analogues of 4-quinolone as an antibacterial compounds. This compounds have a
number of advantages over other classes of antibacterials.
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 They are effective against many Gram positive and Gram negative organisms,
well absorbed orally, well distributed in tissues, relatively long serum half-lives and
minimum toxicity. They are especially useful for urinary tract infections, upper and
lower respiratory track infections, skin infections and bone infections  and for penicilli-
nase resistant sexually transmitted diseases24.
Considerable interest has been around in the chemistry of quinoline due to its
wide spectrum  of biological activities which are described as under
1. Antihypertensive25
2. Bacteriocidal26-28
3. Analgesic29-30
4. Antidepressant31
5. Herbicidal32,33
6. Anticonvulsant34
7. Antitumor35,36
8. Antidiabetic37
9. Antiulcer 38
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These agents have a wide sprectrum of in vitro antibacterial activity,  particular
against Gram-positive bacteria. These agents also have better anti Gram-positive activity,
including improved potency against the pneumococcus strain. Subsequently, newer agents
were developed that had increased anti microbial activity against Gram-positive
pathogens; these included Sparfloxacin47and Grepafloxacin48. (MICs c. 0.25-0.5 mg/L
against Streptococcus pneumoniae). However, Sparfloxacin has now largely been
abandoned because of significant phototoxicity and potential for serious cardiac
dysrhythmia. The third generation agents like Moxifloxacin49, Gatifloxacin50,
Sitafloxacin51, Clinafloxacin52 have enhanced activity against S. pneumoniae (MICs
generally c. 0.12 mg/L). These compounds are active against penicillinase- resistant
S. Pneumoniae and have proven very effective in the treatment of lower respiratory
track infections. (See table 1.1 for structures)
N
F
CH3
O
OH
O
(I)  Flumequin
The structure of newer antibacterial have been developed along two parallel path-
ways, the napthyridones and the fluoroquinolones. The first quinolone, Flumequine42 (I)
was used transiently until ocular toxicity was reported. Shortly afterwards, second
generation agents were developed like, Norfloxacin43, Lomefloxacin44, Pefloxacin45,
Ciprofloxacin46.
10. Antiinflammatory 39
11. Anticancer 40
12. Antimalarial41
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Table 1.1 : Some important 4-Quinolone drugs in use
N NCH3
CH3
OH O
OH
N
CH3
O O
OH
N
NH
F
N
CH3
O O
OH
N
NH
F
F
CH3
N
CH3
O O
OH
N
N
F
CH3
N
O O
OH
N
NH
F
N
O O
OH
N
N
F
CH3
O
CH3
N
O O
OH
N
NH
F
F
NH2
CH3
CH3
N
O O
OH
N
NH
F
NH2
CH3
O
CH3
N
O O
OH
N
NH
F
CH3
CH3
N
O O
OH
F
Cl
NNH2
N
O O
OH
F
N
O
CH3N
H
N
O O
OH
F
N
Cl
F
NH2
       Nalidixic acid Norfloxacin
   Lomefloxacine Pefloxacin
     Ciprofloxacin Ofloxacin
Sparfloxacin   Clinafloxacin
Gatifloxacin Grepafloxacin
Moxifloxacin Sitafloxacin
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Hasegawa et al.53 has prepared 2-Quinolones platinum complexes (II), Which
are useful for treating malignant tumor.
N
O
O
R2
O
R1       OH-
                                                                             Pt+         R2 = -alkyl, NR3R4
     R1 = -H, alkyl
      R3,R4 = -alkyl, Ph
                                                        ( II )
Tomita K.et al.54 have synthesized 3-Benzoyl-4-hydroxy-2-quinolone and
other 3-substituted derivatives (III ) like 3-propenyl, butyryl, isovaleryl, caproyl,
octanoyl and decanoyl were also prepared and studied their antitubercular activity.
N
H
OH O
R
O
     (III)
                                                  R = C2-C11 alkyl
Mohamed et al.55 have studied 3-Heterocyclic-4-hydroxy-6-methyl-2(1H)-
quinolones for its antibacterial and antifungal activity. Shah A.K. et al.56 synthesized
antiinflammatory compounds like N-(2-thiazoly)amides and N-(2-pyridyl)amides of
4-Hydroxy-2-quinolone-3-carboxylic acid.Some of the molecules have high antiexudative
activity (carrageenan edema) than the activity of Sudoxicam. Kappe Thomas and Faber
Kurt et al.57 have reported (4-Hydroxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-
yl)(Tetrazol-5-yl)Ketone and 5-Methyl-2,4-dioxo-2,3,4,5-tetrahydrofuro [3,2-
C]quinoline as an anti-inflammatory agent.
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Afonso et al.58 had synthesized alkyl and acyl substituted quinolone (IV) which
shown antiviral activities against herpes group viruses. In particular, the compounds are
useful against HSV-1 and HSV-2 (Herpes simplex virus)
N O
R1
O O
CH3
O
O CH3
O
O
CH3
R
Uchida et al.59 in1983 have synthesized some carbostyril derivatives,which are
useful for curing peptic ulcer of stomach and duodenum. The compound named
Rebamipide (V) perticularly has prophylaxis and curing effects for treating chronic
ulcers.
N
H
O
NH
O
O OH
Cl
                                        (V)   Rebamipide
Karemmerer and coworkers et al.60  have synthesized substituted N-Alkyl-3-
nitro-pyrano[3,2-C]quinoline-2-ones (VI) and tested as an antiallergic agents.
N
O
O
R
O
N+
O-
OOH
Cl                                                        (VI)       R=-H,alkyl
                                        R1= -CH2Ph, Ph, CH3 etc.
                                                     (IV)
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Trkovnik et al.61  have prepared fused pyrano-4-quinolone derivatives(VII). These
derivatives were tested as antibacterial against various microorganisms like, P.
aenrgiizosa ,  S. pyogens , S. faecalis,  S.aureus and  S.epiderms etc.
N
H
OO
O
O
O
CH3
R= -H,OH,CH3 and CF3
(VII)
Masotoshi et al.62 have reported pyranoquinolines and furoquinoline derivatives
(VIII) for antibacterial agents against methicilin resistant staphylococcus aureus.
R1= -C1-6 alkyl, alkoxy, halo
R2= -R6SO2, R6= -C1-6 alkyl, C1-6 aryl
R3= -C1-6 alkyl, R4, R5= -C1-6 aryl,-C6-10 aryl, heterocyclyl
                                                             (VIII)
El-Tawell and Ibrahim et al.63 have reported the synthesis of several polysubstituted
pyrano[3,2-C]quinolones readily 4-hydroxy-2-quinolones (IX).These compounds were
evaluted for bactericidal activity against Gram negative and Gram positive bacteria.
N
O
R2
R4
R5
R3
R1
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N
O
O
O
N
S
N O
R
where R= CH3, C2H5
          (IX)
Potent, orally active, nonsteroidal androgen receptor agonist (X) were  discovered
by Lawrence G. Hamann, et al.64  Deficiencies in circulating levels of the androgens
testosterone  and dihydrotestosterone (DHT) in hypogonadal men can be compensated
for administration of exogenous androgens65-68 which have proven efficacious in hormone
replacement therapy, abrogating age-related deterioration of muscle and bone69,70 and
regulating plasma lipids.71 Cancer cachexia,72 male contraception73and performance
enhancement74,75
 
 have also been investigated as clinical targets of androgen therapy.76-79
N
H
N
H
O
CF3
CH3
(X)
Atwal and coworkers80 serendipitously observed that pyranoquinoline of type
(XI) possess pure calcium channel blocking activity.
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N O
O
N
O
OH
CH3CH3
(XI)
Novel 4-aryl-3-(hydroxyalkyl)quinoline-2-one derivatives (XII) were prepared
by Piyasena Hewawasam, et al.81and evaluated as openers of the cloned maxi-K channel
relaxants of corporal smooth muscle for erectile dysfunction.
N
H
O
(CH2)n
OHOH
Cl
F3C
(XII)
With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of quinolines which have been  described in
following sections.
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SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-ARYLAMIDO-6,8-DIBROMO-2-CYCLOPROPYL
QUINOLINES.
SECTION - II : SYNTHESIS AND THERAPEUTIC EVALUATION OF
4-CYCLOPROPYL-5,6,7,8 SUBSTITUTED-1,2-DIHYDRO
QUINOLINE-2-ONES.
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF  3-ARYLAMIDO-6,8-
DIBROMO-2-CYCLOPROPYL QUINOLINES.
Quinoline derivatives have remarkable therapeutic activity. Taking this
consideration, we have undertaken the preparation of quinoline derivatives, novel
quinoline derivatives of type (XIII) have been synthesized by the condensation of 2-
Amino-3,5-dibromo benzaldehyde with N-Aryl-3- cyclopropyl-3-oxo-propanamide
in the presence of methansulphonic acid.
    Type (XIII)             R =Aryl
N
Br
Br
O
NH
R
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
O
OMe
O
+
O
O
NHR +
Toluene
R= Aryl
NH2
O
Br
Br
N
NH
O
Br
Br
R
methan sulphonic acid
NH2
R
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Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
 Alkane C – H str.(asym.) 2944 2975-2950 82
 –CH3 C – H str. (sym.) 2831 2880-2860 "
C – H def. (asym.)                          1453 1470-1435 "
   –C–CH2 C – H def.                                       1408 1385-1365 "
   Aromatic C – H str.                                        3008 3090-3030 "
C = C str                                         1517 1612-1550 "
C – H i.p. (def)                               1170 1177-1027 "
C – H o.o.p. (def)                             820 832-802 "
Quinoline C=C 1600 1680-1580 83-84
C –N str. 1280 1300-1200 "
Carboxamide C =O 1647 1680-1630 "
N – H str. 3269 3380-3150 "
   Ether Ar-O-C 1248  1260-1200 "
    Halide C-Br 820 800-600 "
IR SPECTRAL STUDIES OF 3-(p-METHOXYPHENYL)-AMIDO-6,8-DIBROMO-2-CYCLOPROPYL
QUINOLINE.
N
Br
Br
O
NH
O
CH3
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NMR SPECTRAL STUDIES OF 3-(p-METHOXYPHENYL)-AMIDO-6,8-DIBROMO-2-
CYCLOPROPYL QUINOLINE.
1. 1.10-1.43                   m               4H                        HC–(CH2)2
2. 2.58-2.64                   m               1H                        (H2C)2-CH
3. 3.80-3.82                  s               3H                            -OCH3
4. 6.88-8.13                   m               7H                             Ar-H
5. 10.07                  s               1H                             N-H
Internal Standard : TMS; Solvent : DMSO  : Instrument : GEMINI-2000 Spectrometer (400 MHz)
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons Inference
N
Br
Br
O
NH
O
CH3
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYLAMIDO-6,8-
DIBROMO-2-CYCLOPROPYL QUINOLINES.
(A)        Synthesis of 3-(p-Methoxyphenyl)- amido-6,8-dibromo-2-cyclopropyl
            quinoline
A mixture of 2-Amino-3,5-dibromo benzaldehyde (2.78gm, 0.01mol) and 3-
Cyclopropyl-N-(p-methoxyphenyl)-3-oxopropanamide (2.33 gm, 0.01mol) in 50 ml of
toluene containing few drops of methansulphonic acid was refluxed by dean and stark
for 4  hrs. The solution was allowed to cool at 20oC. Resulting solid mass separated was
filtered and crystallized from dioxane.Yield 39%, m.p.212 0C, Anal.Calcd. for C 20  H  16 N2
O 2Br2 Calcd: C, 52.97; H, 4.23; N, 5.88 %, Found:  C, 53.12; H, 4.40; N, 6.02 %.
        TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 3-Arylamido-6,8- dibromo-2-cyclopropyl quinolines. were
prepared. The physical data are recorded in Table No.13.
(B) Biological evaluation of 3-Arylamido-6,8-dibromo-2-cyclopropyl
quinolines.
Antimicrobial testing were carried out as described in Chapter-1, Section-1(B),
Page No.39.The zones of inhibition of test solutions are recorded in Graphical Chart
No.13.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type
(XIII) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=p-
methylphenyl, p-fluorophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= m-methylphenyl, p-chlorophenyl  against S.aureus.
The maximum activity was displayed by the compounds bearing R= m-nitrophenyl,
o-nitrophenyl against Aerogenes. In the case of P.aeruginosa all the compounds were
least active except R= p-chlorophenyl, p-fluorophenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=p-methoxyphenyl, p-
methylphenyl and p-nitrophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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SECTION-II
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-CYCLOPROPYL-5,6,7,8
SUBSTITUTED-1,2-DIHYDRO QUINOLINE-2-ONES.
With an intention of preparing agent with better therapeutic potency  the quinolene
derivatives of type (XIV) have been prepared by the cyclisation of  N-Aryl-3-
cyclopropyl-3-oxo-propanamide with the help of concentrated sulphuric acid.
Type (XIV)
N
H
O
R1
R2
R3
R4
R1,R2,R3,R4=Cl,CH3
OCH3,NO2...
The structure elucidation of synthesized compounds has been done on the basis
of Elemental analyses, Infrared and 1H Nuclear Magnetic Resonance spectroscopy and
further supported by Mass spectrometry. Purity of all compounds has been checked by
thin layer chromatography.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40μg. The biological
activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
O
OMe
O
NH2
R4
R3
R2
R1
+
O
O
NH
R4R3
R2
R1
Toluene
R1,R2,R3,R4 =  H,CH 3, OCH 3, 
N
H
O
R1
R2
R3
R4
Con. sulphuric acid
Cl, Br, NO 2,F
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IR SPECTRAL STUDIES OF   4-CYCLOPROPYL-6- METHYL-1,2-DIHYDRO QUINOLINE-2-ONE.
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2960 2975-2950 82
–CH3 C – H str. (sym.) 2889 2880-2860 "
C – H def. (asym.) 1458 1470-1435 "
–C -CH2 C – H def. 1361 1385-1365 "
Aromatic =C – H str. 3062 3080-3030 "
C = C str 1610 1612-1600 "
1419 1417-1401 "
C – H i.p. (def) 1245 1269-1247 "
1022 1018-1008 "
C – H o.o.p. (def) 825 832-802 "
Quinoline C=N str. 1560 1580-1550 83-84
N – H str. 3523 3440-3300 "
Carboxamide C =O 1647 1680-1630 "
N – H str. 3191 3380-3150 "
N
H
O
CH3
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NMR SPECTRAL STUDIES OF  4-CYCLOPROPYL-6- METHYL-1,2-DIHYDRO QUINOLINE-2-
ONE.
1.      1.80-2.44                   m                4H                       HC–(CH2)2
2.     2.79-2.84                   m                1H                       (H2C)2–CH
3.     3.78-3.82                  s               3H                          Ar–CH3
4.    6.36-7.56                 m               4H                           Ar-H
5.    11.61                s               1H                           N–H
Internal Standard : TMS; Solvent : DMSO  : Instrument : GEMINI-2000 Spectrometer (300 MHz)
Signal
No.
MultiplicitySignal Position
(δ ppm)
Relative No.
of Protons
Inference
N
H
O
CH3
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EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-CYCLOPROPYL-
5,6,7,8 SUBSTITUTED-1,2-DIHYDRO QUINOLINE-2-ONES.
(A) Synthesis of   4-Cyclopropyl-6 methyl-1,2-dihydro quinoline 2-one.
 A mixture of 3-Cyclopropyl-N-(p-methylphenyl)-3-oxopropanamide (2.33 gm,
0.01 mol) and 5ml concentrate sulphuric acid was stirred for 5.0 hrs.at 50OC. The reaction
mass pour on to crushed ice.  Adjust pH of mixture with liq. ammonia. The  resulting
solid mass separated was filtered and crystallized from dioxane. Yield 39 %, m.p.165 0C
Anal.Calcd. for C13H13NO Calcd: C,78.36; H,6.58; N, 7.03%, Found:  C,78.50;
H,6.72; N,7.25%.
TLC System : Ethyl acetate : Hexane (2 : 3)
Similarly, other 4-cyclopropyl-5,6,7,8 substituted-1,2-dihydro quinoline-2-ones.
were prepared. The physical data are recorded in Table No. 14.
(B) Biological evaluation of 4-cyclopropyl-5,6,7,8 substituted-1,2-dihydro
quinoline-2-ones.
Antimicrobial testing were carried out as described in Chapter-1, Section-1(B),
Page No.39. The zones of inhibition of test solutions are recorded in Graphical Chart
No.14.
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RESULTS AND DISCUSSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that all compounds of type
(XIV) were found to be mild to moderately active against Gram positive and Gram
negative bacterial strains.
However the maximum activity was observed in compounds bearing R=m,p-
dichlorophenyl, m-nitrophenyl substituents against B.coccus. The significant activity was
observed in compounds bearing R= p-fluorophenyl, m-nitrophenyl against S.aureus.
The maximum activity was displayed by the compounds bearing R= p-
chlorophenyl, m-methylphenyl against Aerogenes. In the case of P.aeruginosa all the
compounds were least active except R= p-chlorophenyl, p-methylphenyl.
ANTIFUNGAL ACTIVITY
The antifungal data revealed that compounds were least toxic to the fungal strain.
However mild activity was shown by the compounds bearing R=m,p-dichlorophenyl, p-
fluorophenyl against A.niger.
The antibacterial activity was compared with standard drugs like Amoxicillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin and antifungal activity was
compared with standard drug like Griseofulvin.
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